documents incorporated reference specified portions registrants proxy statement filed commission pursuant regulation connection registrants annual meeting stockholders held may incorporated reference part iii report based closing price per share june excludes shares registrants common stock held executive officers directors stockholders whose ownership exceeds registrants common stock outstanding june exclusion shares construed indicate person possesses power direct indirect direct cause direction management policies registrant person controlled common control registrantgilead sciences inc annual report table contents part item business item risk factors item b unresolved staff comments item properties item legal proceedings item mine safety disclosures part ii item market registrants common equity related stockholder matters issuer purchases equity securities item selected financial data item managements discussion analysis financial condition results operations item quantitative qualitative disclosures market risk item financial statements supplementary data item changes disagreements accountants accounting financial disclosure item controls procedures item b information part iii item directors executive officers corporate governance item executive compensation item security ownership certain beneficial owners management related stockholder matters item certain relationships related transactions director independence item principal accountant fees services part iv item exhibits financial statement schedules item summary signatures rights various trademarks copyrights trade names used business including following gilead gilead sciences ambisome atripla biktarvy cayston complera descovy emtriva epclusa eviplera genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada truvadaforprep tybost vemlidy viread vosevi yescarta zydelig lexiscan registered trademark astellas us llc macugen registered trademark eyetech inc symtuza registered trademark janssen sciences ireland uc tamiflu registered trademark hoffmannla roche inc report also includes trademarks service marks trade names companiesthis annual report including section entitled managements discussion analysis financial condition results operations contains forwardlooking statements regarding future events future results subject safe harbors created securities act amended securities act securities exchange act amended exchange act words expect anticipate target goal project hope intend plan believe seek estimate continue may could might forecast variations words similar expressions intended identify forwardlooking statements addition statements statements historical fact forwardlooking statements including statements regarding overall trends operating cost revenue trends liquidity capital needs statements expectations beliefs future plans strategies anticipated events trends similar expressions based forwardlooking statements current expectations future events statements guarantees future performance involve risks uncertainties assumptions difficult predict actual results may differ materially suggested forward looking statements various reasons including identified part item annual report heading risk factors given risks uncertainties cautioned place undue reliance forwardlooking statements forwardlooking statements included report made date hereof except required federal securities laws rules regulations securities exchange commission sec undertake specifically decline obligation update statements publicly announce results revisions forwardlooking statements distribution report whether result new information future events changes assumptions otherwise part item business overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatening illnesses around world operations countries worldwide headquarters foster city california gileads primary areas focus include hivaids liver diseases hematologyoncology inflammationrespiratory diseases seek add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategic collaborations highlights marked operational excellence transition positioned future growth business continued develop deliver innovative medicines help people lifethreatening illnesses around world highlights performance include hiv achieved record sales hiv products hiv product revenues increasing united states worldwide compared growth driven successful launch biktarvy continued strong uptake single tablet regimens containing tenofovir alafenamide taf treatment hiv infection well truvada preexposure prophylaxis prep indication hiv prevention biktarvy oncedaily single tablet regimen containing bictegravir emtricitabine taf treatment hiv infection adults approved us food drug administration fda february european commission june liver diseases revenues chronic hepatitis c virus hcv products became predictable wanted introduce lower priced alternative hcv products without significant disruption healthcare system business authorized launch generic versions epclusa harvoni united states starting january separate subsidiary asegua therapeutics llc asegua also continued advance clinical trials treatment chronic hepatitis b virus hbv nonalcoholic steatohepatitis nash including completing enrollment phase clinical trials nash cell therapy immunooncology advanced pipeline cancer therapies positioned leader cell therapy yescarta approved european commission august treatment relapsed refractory diffuse large bcell lymphoma dlbcl primary mediastinal large bcell lymphoma pmbcl two lines systemic therapy certified additional centers united states europe provide treatment yescarta order advance accelerate research development efforts cell therapy immunooncology year entered key strategic collaborations national cancer institute pfizer inc pfizer sangamo therapeutics inc sangamo gadeta bv gadeta hifibio therapeutics hifibio tango therapeutics tango agenus inc agenus inflammation continued advance pipeline novel investigational agents inflammatory diseases including announcing positive data filgotinib ongoing phase clinical trials also entered strategic collaboration verily life sciences llc alphabet company verily using verilys immunoscape platform identify better understand immunological basis inflammatory diseases year continued invest advance research development pipeline across therapeutic areas end research development pipeline included active clinical studies phase clinical trials additionally completed collaborations partnerships strategic investments reflects commitment enabling access new technologies drug candidates potential evolve care people lifethreatening illnesses investments research development reflect commitment expanding pipeline across range diseases address areas significant unmet medical need positioning longterm growth business principal products innovative medicines represent advancements offering enhanced modes delivery convenient treatment regimens improved resistance profiles reduced side effects greater efficacy focus innovation allowed us deliver marketed products across primary areas focus hivaids liver diseases hematologyoncology inflammationrespiratory diseases principal products approved indications united states follows hivaids biktarvy oral formulation dosed day treatment hiv infection certain patients biktarvy single tablet regimen fixeddose combination antiretroviral medications bictegravir emtricitabine taf descovy oral formulation indicated combination antiretroviral agents treatment hiv infection certain patients descovy fixeddose combination antiretroviral medications emtricitabine taf odefsey oral formulation dosed day treatment hiv infection certain patients odefsey single tablet regimen fixeddose combination antiretroviral medications emtricitabine taf rilpivirine marketed janssen sciences ireland uc one janssen pharmaceutical companies johnson johnson janssen genvoya oral formulation dosed day treatment hiv infection certain patients genvoya single tablet regimen fixeddose combination antiretroviral medicines elvitegravir cobicistat emtricitabine taf stribild oral formulation dosed day treatment hiv infection certain patients stribild single tablet regimen fixeddose combination antiretroviral medications elvitegravir cobicistat tenofovir disoproxil fumarate tdf emtricitabine compleraeviplera oral formulation dosed day treatment hiv infection certain patients product marketed united states complera europe eviplera single tablet regimen fixeddose combination antiretroviral medications tdf emtricitabine janssens rilpivirine hydrochloride atripla oral formulation indicated complete regimen treatment hiv infection certain patients atripla fixeddose combination antiretroviral medications tdf emtricitabine bristolmyers squibb companys bmss efavirenz truvada oral formulation indicated combination antiretroviral agents treatment hiv infection certain patients fixed dose combination antiretroviral medications tdf emtricitabine fda also approved truvada prep indication combination safer sex practices reduce risk sexually acquired hiv infection certain atrisk patients liver diseases vosevi oral formulation oncedaily single tablet regimen sofosbuvir velpatasvir voxilaprevir retreatment chronic hcv infection adults genotype previously treated nsa inhibitorcontaining regimen ii genotype previously treated sofosbuvircontaining regimen without nsa inhibitor vemlidy oral formulation taf dosed day treatment chronic hbv infection adults compensated liver disease epclusa oral formulation oncedaily single tablet regimen sofosbuvir velpatasvir treatment chronic hcv infection adults genotype without cirrhosis compensated cirrhosis ii decompensated cirrhosis use combination ribavirin harvoni oral formulation oncedaily single tablet regimen ledipasvir sofosbuvir treatment chronic hcv infection adults genotype without cirrhosis compensated cirrhosis ii adults genotype infection decompensated cirrhosis combination ribavirin ii adults genotype liver transplant recipients without cirrhosis compensated cirrhosis combination ribavirin iv certain pediatric patients genotype without cirrhosis compensated cirrhosis viread oral formulation tdf dosed day treatment chronic hbv infection adults certain pediatric patients hematologyoncology yescarta axicabtagene ciloleucel car cell therapy treatment adult patients relapsed refractory large bcell lymphoma two lines systemic therapy including dlbcl otherwise specified pmbcl highgrade bcell lymphoma dlbcl arising tfl zydelig idelalisib oral formulation kinase inhibitor treatment patients relapsed chronic lymphocytic leukemia cll combination rituximab rituximab alone would considered appropriate therapy due comorbidities ii relapsed follicular bcell non hodgkin lymphoma fl patients received least two prior systemic therapies iii relapsed small lymphocytic lymphoma received least two prior systemic therapies letairis ambrisentan oral formulation endothelin receptor antagonist treatment pulmonary arterial hypertension pah group improve exercise capacity delay clinical worsening ii combination tadalafil reduce risks disease progression hospitalization worsening pah improve exercise ability ranexa ranolazine oral formulation extendedrelease tablet antianginal treatment chronic angina ambisome amphotericin b liposome injection proprietary liposomal formulation amphotericin b antifungal agent treatment serious invasive fungal infections caused various fungal species adults information product revenues including amount revenue contributed products listed last three fiscal years see note revenues notes consolidated financial statements included item annual report commercialization distribution us international commercial sales operations marketing subsidiaries countries products marketed commercial teams andor conjunction thirdparty distributors corporate partners commercial teams promote products direct field contact physicians hospitals clinics healthcare providers generally grant thirdparty distributors exclusive right promote product territory specified period time agreements distributors provide collaborative efforts distributor gilead obtaining maintaining regulatory approval product specified territory sell distribute products united states exclusively wholesale channel product sales three large wholesalers mckesson corporation amerisourcebergen corporation cardinal health inc accounted total revenues years ended december combined basis wholesalers accounted approximately product sales united states approximately total worldwide revenues sell distribute products europe countries outside united states product approved either commercial teams thirdparty distributors corporate partners competition operate highly competitive environment face significant competition global pharmaceutical biotechnology companies specialized pharmaceutical firms generic drug manufacturers products compete commercially available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance ease use price insurance reimbursement coverage distribution marketing products mature private insurers government payers often reduce amount reimburse patients increases pressure us reduce prices new branded generic products introduced major markets ability maintain pricing market share may affected description competitors see item risk factors face significant competition research development research development rd philosophy strategy develop bestinclass drugs improve safety efficacy unmet medical needs intend continue committing significant resources internal rd opportunities external business development activity product development efforts cover wide range medical conditions including hivaids liver diseases hematologyoncology inflammationrespiratory diseases research scientists engaged discovery development new molecules technologies hope lead approval new medicines advance current standard care address unmet medical needs development product candidates subject various risks uncertainties risks uncertainties include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain regulatory approvals result product candidates may never successfully commercialized drug development inherently risky many product candidates fail drug development process summary key product candidates corresponding current stages development product candidates treatment hivaids product candidates description product phase descovy descovy evaluated prep indication product phase gs gs nucleoside reverse transcriptase inhibitor evaluated treatment hiv infection products phase gs gs capsid inhibitor evaluated treatment hiv infection vesatolimod vesatolimod formerly gs tlr agonist evaluated potential cure hiv infection gs gs broadly neutralizing antibody evaluated potential cure hiv infection product candidates treatment liver diseases product candidates description product phase selonsertib selonsertib ask inhibitor evaluated stellar trial treatment nash bridging fibrosis products phase gs gs tlr agonist evaluated treatment hbv infection cilofexor formerly gs fxr agonist evaluated treatment nash primary biliary cirrhosis cilofexor primary sclerosing cholangitis firsocostat firsocostat formerly gs acc inhibitor evaluated treatment nash product candidates treatment hematologyoncology product candidates description products phase axicabtagene ciloleucel axicabtagene ciloleucel evaluated treatment second line diffuse large bcell lymphoma dlbcl products phase axicabtagene ciloleucel evaluated treatment indolent nonhodgkin lymphoma axicabtagene ciloleucel axicabtagene ciloleucel also evaluated treatment dlbcl combination antipdl mab first line dlbcl tirabrutinib tirabrutinib btk inhibitor evaluated treatment bcell malignancies ktex car cell therapy evaluated treatment mantle cell lymphoma adult pediatric ktex acute lymphoblastic leukemia products phase kite kite mage aa evaluated treatment solid tumors product candidates treatment inflammationrespiratory diseases product candidates description product phase filgotinib jak inhibitor evaluated treatment rheumatoid arthritis crohns disease ulcerative filgotinib colitis products phase filgotinib filgotinib evaluated treatment various inflammatory diseases gs gs syk inhibitor evaluated treatment sjogrens syndrome lupus products phase gs gs tpl inhibitor evaluated treatment inflammatory bowel disease product candidates product candidate description product phase remdesivir remdesivir nuc inhibitor evaluated treatment ebola virus infection addition internal discovery clinical development programs seek add portfolio products product acquisition inlicensing strategic collaborations completed collaborations partnerships strategic investments compared reflects commitment enabling access new technologies drug candidates potential evolve care people lifethreatening illnesses patents proprietary rights us european patent expiration number us foreign patents patent applications rights patents related compounds products technology certain issued patents enforceable provide adequate protection pending patent applications result issued patents following table shows estimated expiration dates including patent term extensions supplementary protection certificates andor pediatric exclusivity granted united states european union primary typically compound patents phase product candidates product candidates fixeddose combinations single tablet regimens estimated patent expiration date provided corresponds latest expiring compound patent one active ingredients single tablet regimen phase product candidates patent expiration product candidate treatment hivaids us eu descovy prep product candidate treatment liver diseases selonsertib treatment nash product candidates treatment hematologyoncology axicabtagene ciloleucel treatment second line diffuse large bcell lymphoma product candidate treatment inflammationrespiratory diseases filgotinib treatment rheumatoid arthritis crohns disease ulcerative colitis application patent term extension filed united states granted would extend us expiration date applications supplementary protection certificates filed european union granted would extend eu expiration date composition matter patent expired european union european union united states patent applications pending relating kites proprietary manufacturing processes following table shows actual estimated expiration dates including patent term extensions supplementary protection certificates andor pediatric exclusivity granted united states european union primary typically compound patents principal products products fixeddose combinations single tablet regimens estimated patent expiration dates provided correspond latest expiring compound patent one active ingredients single tablet regimen products patent expiration us eu letairis ranexa atripla truvada descovy vemlidy compleraeviplera zydelig odefsey yescarta stribild genvoya harvoni epclusa biktarvy vosevi estimated expiration dates include potential additional exclusivity eg patent term extensions supplementary protection certificates pediatric exclusivity yet granted notes gilead watson laboratories inc reached agreement settle patent litigation matter related letairis gilead lupin limited lupin reached agreement settle patent litigation matter related ranexa gilead teva pharmaceuticals reached agreement settle patent litigation concerning patents protect emtricitabine truvada atripla products supplementary protection certificates spcs granted several european countries validity spcs challenged several generic manufacturers many launched competing product validity spcs considered national courts court justice european union composition matter patent expired european union european union united states patent applications pending relating kites proprietary manufacturing processes applications patent term extensions pending united states andor spcs pending one countries european union products application patent term extension filed united states granted would extend us expiration date applications spcs filed european union granted would extend eu expiration date patent protection certain challenges patents proprietary rights important business properly drafted enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology patents covering certain active pharmaceutical ingredients api hiv products well yescarta letairis ranexa held third parties acquired exclusive rights patents agreements parties patents covering ranolazine active ingredient ranexa instead discovered sustainedrelease formulation ranolazine would achieve therapeutic plasma levels obtained patents formulations characteristic plasma levels achieve may obtain patents certain products many years marketing approval obtained patents limited life may begin run prior commercial sale related product commercial value patent may limited however may able apply patent term extensions supplementary protection certificates countries example extensions patents supplementary protection certificates many products granted united states number european countries compensating part delays obtaining marketing approval similar patent term extensions may available products developing certain obtain countries also important infringe valid patents third parties infringe valid patents third parties reputations may harmed may required pay significant monetary damages may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware patents patent applications owned parties parties may claim cover use sofosbuvir axicabtagene ciloleucel bictegravir patent applications confidential period time patent issued may know competitors filed patent applications technology covered pending applications first invent first file application directed toward technology subject patent applications competitors may filed patent applications received patents may obtain additional patents proprietary rights block compete products addition competitors file patent applications covering technology may participate interferencederivation proceedings litigation determine right patent litigation interferencederivation proceedings unpredictable expensive even ultimately successful results operations may adversely affected events patents relating pharmaceutical biopharmaceutical biotechnology products compounds processes cover existing compounds products processes likely file future always provide complete adequate protection future litigation proceedings regarding enforcement validity existing patents future patents could result invalidation patents substantially reduce protection time time certain individuals entities may challenge patents pending patent applications patent applications filed collaborative partners may result issuance patents may result patents provide adequate protection result may able prevent third parties developing compounds products closely related developed developing addition certain countries provide effective enforcement patents thirdparty manufacturers may able sell generic versions products countries description significant pending legal proceedings see note commitments contingencies legal proceedings notes consolidated financial statements included item annual report trade secrets also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors agreements provide confidential information developed made known individual course relationship us kept confidential used disclosed third parties except specified circumstances case employees agreements provide inventions made individual employed us exclusive property certain parties comply confidentiality agreements adequate remedies breach trade secrets otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partner cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions trade secrets confidential information become known independently discovered competitors enter disputes ownership inventions business results operations could adversely affected manufacturing raw materials products manufactured either facilities thirdparty contract manufacturers depend third parties perform manufacturing activities majority api drug products products including hiv hcv products use multiple thirdparty contract manufacturers primary backup suppliers manufacturing sites letairis exclusive manufacturer ambrisentan api another qualified supplier make api yescarta established clinical commercial manufacturing facilities cell processing activities future products continue develop additional manufacturing capabilities establish additional thirdparty suppliers manufacture sufficient quantities product candidates undertake clinical trials manufacture sufficient quantities product approved commercial sale manufacturing facilities lease manufacturing facilities foster city san dimas la verne oceanside el segundo california dublin cork ireland edmonton alberta canada manufacture distribute certain products api clinical andor commercial uses foster city california conduct process chemistry research development activities manufacture api clinical trials oversee third party contract manufacturers san dimas la verne california manufacture ambisome san dimas package label majority commercial products distribute products americas pacific rim oceanside california utilize facility clinical manufacture process development biologics candidates el segundo california utilize facility clinical commercial manufacture processing yescarta cork dublin ireland utilize cork facility commercial manufacture packaging labeling antiviral products also perform quality control testing labeling packaging final release many products distribution european union international markets dublin facility also responsible distribution activities products edmonton alberta canada conduct process chemistry research scaleup activities clinical development candidates manufacture api investigational commercial products conduct chemical development activities improve existing commercial manufacturing processes thirdparty manufacturers believe technology use manufacture products proprietary products manufactured thirdparty contract manufacturers disclosed necessary aspects technology enable manufacture products us agreements thirdparty manufacturers intended restrict using revealing technology certain thirdparty manufacturers comply restrictions addition thirdparty manufacturers could develop technology related work perform us may need manufacture products could required enter additional agreements thirdparty manufacturers want use technology allow another manufacturer use technology thirdparty manufacturer could refuse allow us use technology could demand terms use technology acceptable us information thirdparty manufacturers see item risk factors manufacturing problems including thirdparty manufacturers corporate partners could cause inventory shortages delay product shipments regulatory approvals may adversely affect results operations regulation manufacturing process manufacturing process pharmaceutical products highly regulated regulators may shut manufacturing facilities believe comply regulations thirdparty manufacturers corporate partners subject current good manufacturing practices extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda european medicines agency ema similar regulations effect jurisdictions manufacturing operations subject routine inspections regulatory agencies yescarta required fda comply risk evaluation mitigation strategy program includes educating certifying medical personnel regarding therapy procedures potential side effect profile therapy potential adverse side effects related cytokine release syndrome neurologic toxicities additionally required maintain complex chain identity custody respect patient material material moves manufacturing facilities manufacturing process back patient access raw materials need access certain raw materials conduct clinical trials manufacture products raw materials generally available multiple sources purchased worldwide normally available quantities adequate meet needs business attempt manage risks associated supply chain inventory management relationship management evaluation alternative sources feasible information see item risk factors may able obtain materials supplies necessary conduct clinical trials manufacture sell products would limit ability generate revenues seasonality operations backlog worldwide product sales reflect significant degree seasonality enduser demand united states fluctuations wholesaler inventory levels impacted product sales observed strong wholesaler sub wholesaler purchases products fourth quarter resulted inventory drawdown wholesalers subwholesalers subsequent first quarter several factors including government budgets annual grant cycles federal state funds buying patterns impacted product sales recorded particular quarter information see item risk factors inability accurately predict demand products uptake new products fluctuations customer inventories makes difficult us accurately forecast sales may cause forecasted revenues earnings fluctuate could adversely affect financial results stock price part operate markets characterized short lead times absence significant backlogs believe backlog information material business whole government regulation operations activities subject extensive regulation numerous government authorities united states european union countries including laws regulations governing testing manufacture safety efficacy labeling storage record keeping approval advertising promotion products result regulations product development product approval processes expensive time consuming regulatory requirements applicable drug development approval subject change legal regulatory changes may impact operations future countrys regulatory agency fda united states emaeuropean commission european union must approve drug sold respective country countries general process drug approval united states summarized many countries including countries european union similar regulatory structures preclinical testing test drug candidate humans must study drug laboratory experiments animals generate data support drug candidates potential benefits safety submit data fda investigational new drug ind application seeking approval test compound humans clinical trials fda accepts ind drug candidate studied human clinical trials determine drug candidate safe effective clinical trials involve three separate phases often overlap take many years expensive three phases subject considerable regulation follows phase drug candidate given small number healthy human control subjects patients suffering indicated disease test safety dose tolerance pharmacokinetics metabolism distribution excretion phase drug candidate given limited patient population determine effect drug candidate treating disease best dose drug candidate possible side effects safety risks drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous extensive phase clinical trials phase drug candidate appears effective safe phase clinical trials phase clinical trials commenced confirm results phase clinical trials conducted longer term involve significantly larger population conducted numerous sites different geographic regions carefully designed provide reliable conclusive data regarding safety benefits drug candidate uncommon drug candidate appears promising phase clinical trials fail rigorous extensive phase clinical trials fda approval process believe data clinical trials show acceptable benefitrisk profile submit appropriate filing usually form new drug application nda supplemental nda fda seeking approval sell drug candidate particular use fda may hold public hearing independent advisory committee expert advisors asks additional questions makes recommendations regarding drug candidate committee makes recommendation fda binding generally followed fda fda agrees compound met required level safety efficacy particular use allow us sell drug candidate united states use unusual however fda reject application believes drug candidate safe enough efficacious enough believe data submitted reliable conclusive point process development drug candidate stopped number reasons including safety concerns lack treatment benefit certain clinical trials currently conducting conduct future completed successfully within specified time period may choose fda may require us delay suspend clinical trials time appears patients exposed unacceptable health risk drug candidate appear sufficient treatment benefit fda may also require phase nonregistrational studies explore scientific questions characterize safety efficacy commercial use drug fda may also require us provide additional data information improve manufacturing processes procedures facilities may require extensive surveillance monitor safety benefits product candidates determines filing contain adequate evidence safety benefits drug addition even fda approves drug could limit uses drug fda withdraw approvals believe complying regulatory standards problems uncovered occur approval addition obtaining fda approval drug obtain fda approval manufacturing facilities drug sell including companies manufacture drugs us facilities subject periodic inspections fda fda must also approve foreign establishments manufacture products sold united states facilities subject periodic regulatory inspection manufacturing facilities located california also must licensed state california compliance local regulatory requirements manufacturing facilities canada ireland also must obtain local licenses permits compliance local regulatory requirements drugs treat serious lifethreatening diseases conditions adequately addressed existing drugs development program designed address unmet medical need may designated fast track candidates fda may eligible priority review drugs treatment hiv infection designated use us presidents emergency plan aids relief may also qualify expedited review european union approval process drugs also subject extensive regulation outside united states european union centralized approval procedure authorizes marketing product countries european union centralized approval procedure used approval one country european union used obtain approval another country european union one two simplified application processes mutual recognition procedure decentralized procedure rely principle mutual recognition receiving regulatory approval european registration procedures separate pricing reimbursement approvals also required countries european union also requirements approval manufacturing facilities products approved sale european regulatory authorities pricing reimbursement successful commercialization products depends part availability governmental thirdparty payer reimbursement cost products related treatments markets sell products government health authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services significant portion sales majority products subject substantial discounts list prices result price increases implement time time certain products may limited effect product sales certain markets addition standard reimbursement structures may adequately reimburse innovative therapies products mature private insurers government payers often reduce amount reimburse patients increases pressure us reduce prices new branded generic products introduced major markets ability maintain pricing market share may affected information see item risk factors existing products subject reimbursement government agencies third parties pharmaceutical pricing reimbursement pressures may reduce profitability inability accurately predict demand products uptake new products fluctuations customer inventories make difficult us accurately forecast sales may cause forecasted revenues earnings fluctuate could adversely affect financial results stock price patient assistance programs recently enhanced scrutiny companysponsored patient assistance programs including insurance premium copay assistance programs donations thirdparty charities provide assistance also enhanced scrutiny governments reimbursement support offerings clinical education programs promotional speaker programs agents vendors donation recipients deemed failed comply laws regulations government guidance areas could subject criminal civil sanctions similar violations competitors could also negatively impact industry reputation increase scrutiny business products health care fraud abuse laws antibribery laws subject various federal state laws pertaining health care fraud abuse including antikickback laws false claim laws antikickback laws make illegal prescription drug manufacturer solicit offer receive pay remuneration exchange induce referral business including purchase prescription particular drug due breadth statutory provisions increasing attention given law enforcement authorities possible certain practices may challenged antikickback similar laws false claims laws generally prohibit anyone knowingly presenting causing presented false fraudulent claim payment federal certain state payers including medicare medicaid knowingly making using causing made used false record statement material false fraudulent claim sales marketing patient support medical activities may subject scrutiny laws addition us foreign corrupt practices act similar worldwide antibribery laws generally prohibit companies intermediaries making improper payments purpose obtaining retaining business policies mandate compliance antibribery laws operate parts world experienced governmental corruption degree certain circumstances strict compliance antibribery laws may conflict local customs practices may require us interact doctors hospitals may state controlled manner different local custom despite training compliance program internal control policies procedures may protect us reckless criminal acts committed employees agents violations fraud abuse laws antibribery laws may punishable criminal andor civil sanctions including fines civil monetary penalties well possibility exclusion federal health care programs including medicare medicaid violations also lead imposition corporate integrity agreement similar government oversight program us healthcare reform us federal state governments continue propose pass legislation designed regulate healthcare industry including legislation seeks indirectly directly regulate pharmaceutical drug pricing information see item risk factors results operations may adversely affected current potential future healthcare legislative regulatory actions laws regulations applicable health care industry could impose new obligations us require us change business practices restrict operations future employees january approximately employees believe good relations employees environment subject number laws regulations require compliance federal state local regulations protection environment regulatory landscape continues evolve anticipate additional regulations near future laws regulations implemented consideration mitigate effects climate change mainly caused greenhouse gas emissions business energy intensive therefore anticipate subject cap trade system mitigation measure would materially impact capital expenditures operations competitive position information subject information requirements exchange act therefore file periodic reports proxy information statements information sec sec maintains website httpwwwsecgov contains reports proxy information statements information regarding issuers file electronically sec mailing address headquarters lakeside drive foster city california telephone number location website wwwgileadcom link investors website sec filings section make available following filings free charge soon reasonably practicable electronically filed furnished sec annual reports quarterly reports form q current reports form k amendments reports filed furnished pursuant section exchange act transactions iran engage transactions within iran would require disclosure annual report item risk factors evaluating business carefully consider following risks addition information annual report manifestation following risks could materially adversely affect business results operations financial condition note factors investors permitted private securities litigation reform act possible predict identify factors therefore consider following risks complete statement potential risks uncertainties face substantial portion revenues derived sales products treat hiv hcv unable increase hiv sales hcv sales decrease anticipated results operations may adversely affected receive substantial portion revenue sales products treatment hiv infection year ended december sales hiv products accounted approximately total product sales expect hiv products account higher percentage total product sales hiv products contain tenofovir alafenamide taf tenofovir disoproxil fumarate tdf andor emtricitabine belong nucleoside class antiviral therapeutics treatment paradigm hiv changes causing nucleosidebased therapeutics fall favor unable maintain increase hiv product sales results operations would likely suffer would likely need scale back operations including future drug development spending research development rd efforts year ended december sales products treatment chronic hepatitis c virus hcv infection accounted approximately total product sales hcv revenues declined expect decline product sales compared major markets drivers hcv product revenues patient starts net pricing market share treatment duration treatment duration stabilizing pricing largely stabilizing expect continue compete market share across market segments geographies anticipate patient starts continue steadily decline predictable unexpected adverse changes drivers including larger anticipated shifts may adversely impact hcv product revenues addition future sales hiv hcv products depend part extent reimbursement products private public payers may continue experience global pricing pressure could result larger discounts rebates products delayed reimbursement negatively impacts product sales results operations also private public payers choose exclude products formulary coverage lists limit types patients coverage provided would negatively impact demand revenues products change formulary coverage reimbursement levels discounts rebates offered products payers may impact anticipated revenues unable achieve forecasted hiv hcv sales stock price could adversely impacted may unable sustain increase sales hiv hcv products number reasons including limited reasons discussed following products used longer period time many patients combination products additional studies conducted new issues respect safety resistance interactions drugs may arise could cause us provide additional warnings contraindications labels narrow approved indications halt sales product could reduce revenues products mature private insurers government payers often reduce amount reimburse patients products increases pressure us reduce prices physicians see benefit hiv hcv products sales hiv hcv products limited new branded generic products introduced major markets ability maintain pricing market share may affected fail commercialize new products expand indications existing products prospects future revenues results operations may adversely affected introduce new products increase sales existing products able increase maintain total revenues continue expand rd efforts results operations may adversely affected drug development inherently risky many product candidates fail drug development process may decide terminate product development expending significant resources effort example recently announced kite anti bcell maturation antigen antibcma evaluated treatment multiple myeloma moving forward also recently announced stellar phase study evaluating safety efficacy selonsertib patients compensated cirrhosis due nonalcoholic steatohepatitis nash meet prespecified week primary endpoint addition unable obtain regulatory approval product candidates future revenue growth results operations may adversely impacted future marketing applications file may approved regulatory authorities timely basis even marketing approval granted may significant limitations use inability accurately predict demand products uptake new products fluctuations customer inventories makes difficult us accurately forecast sales may cause forecasted revenues earnings fluctuate could adversely affect financial results stock price may unable accurately predict demand products including uptake new products demand depends number factors example nonretail sector united states includes government institutions including state aids drug assistance programs adaps us department veterans affairs correctional facilities large health maintenance organizations tends even less consistent terms buying patterns often causes quarteroverquarter fluctuations necessarily mirror patient demand products federal state budget pressures well annual grant cycles federal state funds may cause purchasing patterns reflect patient demand products example first quarters certain prior years observed large nonretail purchases hiv products number state adaps exceeded patient demand believe purchases driven grant cycle federal adap funds expect continue experience fluctuations purchasing patterns nonretail customers may result fluctuations product sales revenues earnings future light budget crises faced many european countries observed variations purchasing patterns induced cost containment measures europe believe measures caused government agencies purchasers reduce inventory products distribution channels decreased revenues caused fluctuations product sales earnings may continue see trend future sell distribute products united states exclusively wholesale channel year ended december approximately product sales united states three wholesalers amerisourcebergen corp cardinal health inc mckesson corp us wholesalers entered inventory management agreements make estimates determine end user demand may completely effective matching inventory levels actual end user demand result changes inventory levels held wholesalers cause operating results fluctuate unexpectedly sales wholesalers match end user demand addition inventory held retail pharmacies nonwholesaler locations inventory management agreements control buying patterns adverse changes economic conditions increased competition factors may cause retail pharmacies reduce inventories products would reduce orders wholesalers consequently wholesalers orders us even end user demand changed example fourth quarter strong wholesaler sub wholesaler purchases products resulted inventory drawdown wholesalers subwholesalers first quarter inventory distribution channel fluctuates quarter quarter may continue see fluctuations earnings mismatch prescription demand products revenues addition estimate rebates required pay connection sales particular quarter based claims data prior quarters united states actual rebate claims typically made payers one three quarters arrears actual claims may vary significantly estimates cause adjustment product revenues extent actual anticipated product revenues exceed fall short investors expectations stock price could adversely impacted yescarta chimeric antigen receptor car cell therapy represents novel approach cancer treatment creates significant challenges us may impact ability increase sales yescarta yescarta car cell therapy involves harvesting cells patients blood ii engineering cells express cancerspecific receptors iii increasing number engineered cells iv infusing functional cancerspecific cells back patient advancing novel personalized therapy creates significant challenges including educating certifying medical personnel regarding procedures potential side effect profile therapy potential adverse side effects related cytokine release syndrome neurologic toxicities compliance risk evaluation mitigation strategy rems program required fda yescarta using medicines manage adverse side effects therapy tocilizumab corticosteroids may available sufficient quantities may adequately control side effects andor may detrimental impact efficacy treatment developing robust reliable process limiting contamination risks engineering patients cells ex vivo infusing engineered cells back patient conditioning patients chemotherapy advance administering therapy may increase risk adverse side effects use engineered cells potential cancer treatment recent development may broadly accepted physicians patients hospitals cancer treatment centers payers others medical community may able establish demonstrate medical community commercial governmental payers safety efficacy yescarta potential advantages compared existing future therapeutics fail overcome significant challenges sales yescarta results operations stock price could adversely affected face significant competition face significant competition global pharmaceutical biotechnology companies specialized pharmaceutical firms generic drug manufacturers products compete available products based primarily efficacy safety tolerability acceptance doctors ease patient compliance ease use price insurance reimbursement coverage distribution marketing tafcontaining hiv products compete primarily products viiv healthcare company viiv also face competition generic hiv products generic versions efavirenz component atripla available united states canada europe observed pricing pressure related efavirenz component atripla sales tdf one active pharmaceutical ingredients truvada atripla compleraeviplera stribild faces generic competition european union united states certain countries addition emtricitabine active pharmaceutical ingredient truvada faces generic competition european union truvada also faces generic competition european union certain countries outside united states hcv products compete primarily products marketed abbvie merck hbv products face competition existing therapies treating patients hbv well generic versions tdf hbv products also compete products marketed bristolmyers squibb company novartis pharmaceuticals corporation novartis yescarta competes car cell therapy marketed novartis expected compete products companies developing advanced cell therapies letairis competes products marketed actelion pharmaceuticals us inc united therapeutics corporation pfizer inc us patent ambrisentan active pharmaceutical ingredient letairis expired july letairis expected face competition manufacturers generic versions letairis united states ranexa competes predominantly generic compounds three distinct classes drugs treatment chronic angina united states including generic andor branded betablockers calcium channel blockers longacting nitrates ranexa expected face competition manufacturers generic versions ranexa united states starting first quarter addition number companies pursuing development technologies competitive existing products research programs competing companies include specialized pharmaceutical firms large pharmaceutical companies acting either independently together pharmaceutical companies furthermore academic institutions government agencies public private organizations conducting research may seek patent protection may establish collaborative arrangements competitive products programs competitors gain market share result new technologies commercialization strategies otherwise could adversely affect results operations stock price results operations may adversely affected current potential future healthcare legislative regulatory actions legislative regulatory actions affecting government prescription drug procurement reimbursement programs occur relatively frequently united states affordable care act aca enacted expand healthcare coverage since numerous efforts made repeal amend administratively limit aca whole part example tax cuts jobs act signed law president trump repealed individual health insurance mandate considered key component aca december texas federal district court struck aca ground individual health insurance mandate unconstitutional although ruling stayed pending appeal ongoing challenges aca resulted uncertainty regarding future viability destabilization health insurance market resulting impact business uncertain could material efforts control prescription drug prices could also material adverse effect business example president trump secretary us department health human services hhs released american patients first blueprint begun implementing certain portions initiative includes proposals increase generic drug biosimilar competition enable medicare program negotiate drug prices directly improve transparency regarding drug prices ways lower consumers ' outofpocket costs trump administration also proposed establish international pricing index would used benchmark determine costs drugs medicare part b addition many states proposed enacted legislation seeks indirectly directly regulate pharmaceutical drug pricing requiring biopharmaceutical manufacturers publicly report proprietary pricing information place maximum price ceiling pharmaceutical products purchased state agencies example californias governor signed prescription drug price transparency state bill law requiring prescription drug manufacturers provide advance notice explanation price increases certain drugs exceed specified threshold similar bills introduced federal level initiatives legislation may cause added pricing pressures products changes medicaid program federal state level could also material adverse effect business proposals could impact coverage reimbursement products including giving states flexibility manage drugs covered medicaid program permitting reimportation prescription medications canada countries could material adverse effect limiting products use coverage furthermore state medicaid programs could request additional supplemental rebates products result increase federal base medicaid rebate extent private insurers managed care programs follow medicaid coverage payment developments could use enactment increased rebates exert pricing pressure products adverse effects may magnified adoption lower payment schedules proposed regulatory actions affecting manufacturers could material adverse effect business example december hhs proposed rule would modify medicare part protected class policy provide part plan sponsors broader authority impose step therapy prior authorization utilization management controls products part protected classes including hiv products january hhs also proposed rule would remove regulatory protection discount safe harbor federal antikickback statute manufacturer rebates paid part plan sponsors medicaid managed care organizations pharmacy benefit managers contract would create new safe harbors arrangements entities difficult predict impact proposed legislative regulatory actions resulting state actions use reimbursement products united states results operations may adversely affected existing products subject reimbursement government agencies third parties pharmaceutical pricing reimbursement pressures may reduce profitability successful commercialization products depends part availability governmental thirdparty payer reimbursement cost products related treatments markets sell products government health authorities private health insurers organizations generally provide reimbursement united states european union significant potentially significant markets products product candidates government authorities thirdparty payers increasingly attempting limit regulate price medical products services substantial portion sales majority products subject significant discounts list price addition standard reimbursement structures may adequately reimburse innovative therapies example effective october centers medicare medicaid services cms established inpatient reimbursement patients receiving yescarta reimbursement includes payment severity adjusted diagnosis related group drg new technology addon payment ntap yescarta cover one half cost yescarta may cover less cases outlier payment taken together total payment may sufficient reimburse hospitals cost care patients receiving yescarta payment methodology likely effect least september limited payments could impact willingness hospitals offer therapy doctors recommend therapy could lessen attractiveness therapy patients could adverse effect sales yescarta results operations cms also proposed national coverage decision car cells would impose certain coverage limitations therapy coverage limitations would apply entire medicare program includes among things requirement patients enrolled clinical trial registry order hospital physician paid car cell therapy commercial payers may follow medicare coverage policies could impose similar limitations additionally european union barriers reimbursement individual countries could limit uptake yescarta laws regulations applicable health care industry could impose new obligations us require us change business practices restrict operations future health care industry subject various federal state international laws regulations pertaining drug reimbursement rebates price reporting health care fraud abuse data privacy security united states laws include antikickback false claims laws laws regulations relating medicare medicaid programs federal state programs medicaid rebate statute individual state laws relating pricing sales marketing practices health insurance portability accountability act hipaa federal state laws relating privacy security health information violations laws related regulations may punishable criminal andor civil sanctions including instances substantial fines civil monetary penalties exclusion participation federal state health care programs including medicare medicaid veterans administration health programs federal employee health benefit programs actions executives overseeing business burdensome remediation measures addition laws regulations broad scope subject change evolving interpretations could require us incur substantial costs associated compliance alter one sales marketing practices violations laws allegations violations could also result negative publicity consequences could harm reputation disrupt business adversely affect results operations events occur business stock price could materially adversely affected recently enhanced scrutiny companysponsored patient assistance programs including insurance premium copay assistance programs donations thirdparty charities provide assistance also enhanced scrutiny governments reimbursement support offerings clinical education programs promotional speaker programs agents vendors donation recipients deemed failed comply laws regulations government guidance areas could subject criminal civil sanctions similar violations competitors could also negatively impact industry reputation increase scrutiny business products description government investigations related litigation see note commitments contingencies notes consolidated financial statements included item annual report engaged may future engage business acquisitions licensing arrangements strategic collaborations disposal assets could cause us incur significant expenses could adversely affect financial condition results operations engaged may future engage business acquisitions licensing arrangements strategic collaborations disposal assets part business strategy may identify suitable transactions future may complete transactions timely manner cost effective basis may realize expected benefits successful making acquisition products technologies acquired may successful may require significantly greater resources investments originally anticipated may able integrate acquisitions successfully existing business could incur assume significant debt unknown contingent liabilities also conduct annual impairment testing goodwill indefinite lived intangible assets fourth quarter earlier impairment indicators exist required us generally accepted accounting principles fail overcome risks could cause us incur significant expenses negatively affect profitability could adverse effect results operations could also experience negative effects reported results operations acquisition dispositionrelated charges amortization expenses related intangibles charges impairment longterm assets approximately product sales occur outside united states currency fluctuations hedging expenses may cause earnings fluctuate could adversely affect stock price significant percentage product sales denominated foreign currencies primarily euro face exposure adverse movements foreign currency exchange rates us dollar strengthens foreign currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative value sales increases overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar use foreign currency exchange forward option contracts hedge percentage forecasted international sales primarily denominated euro also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid foreign currency exchange net hedges favorable impact product sales million year ended december compared period predict future fluctuations foreign currency exchange rates us dollar us dollar appreciates significantly certain currencies hedging program sufficiently offset effects appreciation results operations adversely affected stock price may decline additionally expenses recognize relation hedging activities also cause earnings fluctuate level hedging expenses recognize particular period impacted changes interest rate spreads foreign currencies hedge us dollar significant safety issues arise marketed products product candidates reputation may harmed future sales may reduced would adversely affect results operations data supporting marketing approvals products forming basis safety warnings product labels obtained controlled clinical trials limited duration cases postapproval use products used longer periods time many patients underlying health problems taking numerous medicines expect continue find new issues safety resistance drug interaction issues may require us provide additional warnings contraindications labels narrow approved indications could reduce market acceptance products regulatory authorities moving towards active transparent pharmacovigilance making greater amounts standalone safety information clinical trial data directly available public websites means periodic safety update report summaries risk management plan summaries various adverse event data safety information without appropriate context expertise may misinterpreted lead misperception legal action may potentially cause product sales stock price decline serious safety resistance drug interaction issues arise marketed products sales products could limited halted us regulatory authorities results operations would adversely affected operations depend compliance complex fda comparable international regulations failure obtain broad approvals timely basis maintain compliance could delay halt commercialization products products develop must approved marketing sale regulatory authorities approved subject extensive regulation fda european medicines agency ema comparable regulatory agencies countries continuing clinical trials many products currently approved additional uses anticipate file marketing approval additional countries additional indications products next several years products may fail receive marketing approvals timely basis manufacture sell products subject extensive regulation review discovery previously unknown problems marketed products problems manufacturing safety reporting promotional activities may result restrictions products including withdrawal products market fail comply applicable regulatory requirements including related promotion manufacturing could subject penalties including fines suspensions regulatory approvals product recalls seizure products criminal prosecution example fda rules often required conduct postapproval clinical studies assess known serious risk signals serious risk identify unexpected serious risk implement rems products could include medication guide patient package insert communication plan healthcare providers elements fda deems necessary assure safe use drug could include imposing certain restrictions distribution use product failure comply requirements imposed fda could result significant civil monetary penalties operating results may adversely affected face risks clinical trials including potential unfavorable results delays anticipated timelines disruption would adversely affect prospects future revenue growth results operations required demonstrate safety efficacy products develop intended use extensive preclinical studies clinical trials results preclinical early clinical studies always accurately predict results later largescale clinical trials even successfully completed largescale clinical trials may result marketable products example recently announced kite antibcma evaluated treatment multiple myeloma moving forward also recently announced stellar phase study evaluating safety efficacy selonsertib patients compensated cirrhosis due nash meet prespecified week primary endpoint product candidates fails achieve primary endpoint clinical trials safety issues arise results clinical trials otherwise inadequate support regulatory approval product candidates commercialization product candidate could delayed halted addition may also face challenges clinical trial protocol design clinical trials product candidates pipeline delayed terminated prospects future revenue growth results operations would adversely impacted example face numerous risks uncertainties product candidates including descovy preexposure prophylaxis prep selonsertib treatment nash axicabtagene ciloleucel treatment second line diffuse large bcell lymphoma filgotinib treatment rheumatoid arthritis crohns disease ulcerative colitis currently phase clinical trials could prevent completion development product candidates risks include ability enroll patients clinical trials possibility unfavorable results clinical trials need modify delay clinical trials perform additional trials risk failing obtain fda regulatory body approvals result product candidates may never successfully commercialized example fda requested conduct safety study filgotinib men ulcerative colitis manta study enrollment manta study likely rate limiting factor filing nda filgotinib united states may make strategic decision discontinue development product candidates example believe commercialization difficult relative opportunities pipeline programs others pipeline completed timely basis prospects future revenue growth results operations may adversely impacted addition clinical trials involving commercial products could raise new safety issues existing products could turn adversely affect results operations harm business addition extensively outsource clinical trial activities usually perform small portion startup activities inhouse rely independent thirdparty contract research organizations cros perform clinical studies including document preparation site identification screening preparation prestudy visits training program management patient enrollment ongoing monitoring site management bioanalytical analysis many important aspects services performed us cros direct control dispute disruption relationship cros clinical trials may delayed moreover regulatory submissions rely quality validity clinical work performed thirdparty cros cros processes methodologies results determined invalid inadequate clinical data results related regulatory approvals could adversely affected depend relationships third parties sales marketing performance technology development logistics commercialization products failure maintain relationships poor performance companies disputes third parties could negatively impact business rely number collaborative relationships third parties sales marketing performance certain territories example collaboration arrangements janssen sciences ireland uc odefsey compleraeviplera symtuza countries rely international distributors sales certain products relationships also involve clinical development products partners reliance collaborative relationships poses number risks including risk unable control resources corporate partners devote programs products disputes may arise respect ownership rights technology developed corporate partners disagreements corporate partners could cause delays termination research development commercialization product candidates result litigation arbitration contracts corporate partners may fail provide significant protection may fail effectively enforced one partners fails perform corporate partners considerable discretion electing whether pursue development additional products may pursue alternative technologies products either collaboration competitors corporate partners marketing rights may choose pursue competing technologies devote fewer resources marketing products products development distributors corporate partners may unable pay us given risks great deal uncertainty regarding success current future collaborative efforts efforts fail product development commercialization new products could delayed revenues products could decline addition rely third party sites collect patient white blood cells known apheresis centers shippers couriers hospitals logistical collection patients white blood cells ultimate delivery yescarta patients disruption difficulties incurred vendors could result product loss regulatory action harm yescarta business reputation ensure apheresis center prepared ship cells manufacturing facilities plan conduct quality certifications apheresis center however apheresis centers may choose participate certification process may unable complete certification timely manner could delay restrain manufacturing commercialization efforts result sales yescarta may limited could harm results operations success depends significant degree ability defend patents intellectual property rights domestically internationally may able obtain effective patents protect technologies use competitors patents proprietary rights important business success depends significant degree ability obtain patents licenses patent rights preserve trade secrets internal knowhow defend infringement patents efforts invalidate operate without infringing intellectual property others properly drafted enforceable patent difficult competitors use technology create competitive products difficult competitors obtain patent prevents us using technology create part business strategy actively seek patent protection united states internationally file additional patent applications appropriate cover improvements compounds products technology patent applications confidential period time patent issued result may know competitors filed patent applications technology covered pending applications first invent first file application directed toward technology subject patent applications addition competitors file patent applications covering technology may participate litigation postgrant proceedings us patent trademark office proceedings determine right patent validity patent granted litigation postgrant proceedings us patent trademark office proceedings unpredictable expensive could divert management attention operations even ultimately successful results operations may adversely affected events generic manufacturers sought may continue seek fda approval market generic versions products abbreviated new drug application anda application process typically used manufacturers seeking approval generic drug description anda litigation see note commitments contingencies notes consolidated financial statements included item annual report entry generic versions products may lead market share price erosion negative impact business results operations success depends large part ability operate without infringing upon patents proprietary rights third parties infringe valid patents third parties may required pay significant monetary damages may prevented commercializing products may required obtain licenses third parties may able obtain alternative technologies required license commercially reasonable terms fail obtain licenses alternative technologies may unable develop commercialize products example aware patents patent applications owned third parties parties may claim cover use sofosbuvir axicabtagene ciloleucel bictegravir see also description litigation regarding sofosbuvir axicabtagene ciloleucel bictegravir note commitments contingencies notes consolidated financial statements included item annual report also aware us patent nos assigned us department health human services purport claim process protecting primate host infection immunodeficiency retrovirus administering combination emtricitabine tenofovir tdf prior exposure host immunodeficiency retrovirus contact us department health human services scope relevance patents explained believe patents valid patent office given relevant prior art physicians patients using claimed methods years centers disease control prevention filed applications patents furthermore also rely unpatented trade secrets improvements unpatented internal knowhow technological innovation example great deal liposomal manufacturing expertise key component liposomal technology covered patents instead protected trade secret protect rights mainly confidentiality agreements corporate partners employees consultants vendors certain parties comply confidentiality agreements adequate remedies breach trade secrets internal knowhow technological innovation otherwise become known independently discovered competitors rd agreements inventions become jointly owned us corporate partner cases become exclusive property one party certain circumstances difficult determine owns particular invention disputes could arise regarding inventions trade secrets internal knowhow technological innovation confidential information become known independently discovered competitors enter disputes ownership inventions business results operations could adversely affected manufacturing problems including thirdparty manufacturers corporate partners could cause inventory shortages delay product shipments regulatory approvals may adversely affect results operations order generate revenue products must able produce sufficient quantities products satisfy demand many products result complex manufacturing processes manufacturing process pharmaceutical products also highly regulated regulators may shut manufacturing facilities believe comply regulations products either manufactured facilities thirdparty manufacturers corporate partners depend third parties perform manufacturing activities effectively timely basis majority solid dose products thirdparty manufacturers corporate partners subject good manufacturing practices gmp extensive regulations governing manufacturing processes stability testing record keeping quality standards defined fda ema similar regulations effect jurisdictions thirdparty manufacturers corporate partners independent entities subject unique operational financial risks control thirdparty manufacturers corporate partners fail perform required could impair ability deliver products timely basis receive royalties could cause delays clinical trials applications regulatory approval may writeoff costs manufacturing batch fails pass quality inspection meet regulatory approval addition thirdparty manufacturers corporate partners may able produce products one limited number facilities therefore limited manufacturing capacity certain products may able locate additional replacement facilities reasonable basis sales products could also adversely impacted reliance limited number facilities extent risks materialize affect performance obligations us financial results may adversely affected manufacturing operations subject routine inspections regulatory agencies unable remedy deficiencies cited fda inspections currently marketed products timing regulatory approval products development could adversely affected risk regulatory agencies countries marketing applications pending undertake similar additional reviews apply heightened standard review could delay regulatory approvals products countries approval product candidates delayed production marketed products interrupted anticipated revenues stock price would adversely affected may able obtain materials supplies necessary conduct clinical trials manufacture sell products would limit ability generate revenues need access certain supplies products conduct clinical trials manufacture products unable purchase sufficient quantities materials find suitable alternate materials timely manner development efforts product candidates may delayed ability manufacture products would limited would limit ability generate revenues suppliers key components materials must named new drug application marketing authorization application filed regulatory authority product candidate seeking marketing approval significant delays occur qualification new supplier required even manufacturer qualified regulatory authority manufacturer must continue expend time money effort area production quality control ensure full compliance gmp manufacturers subject regular periodic inspections regulatory authorities following initial approval result inspections regulatory authority determines equipment facilities laboratories processes comply applicable regulations conditions product approval regulatory authority may suspend manufacturing operations manufacturing operations single suppliers products suspended may unable generate sufficient quantities commercial clinical supplies product meet market demand would turn decrease revenues harm business addition delivery material suppliers interrupted reason may unable ship certain products commercial supply supply products development clinical trials addition products materials utilize operations made one facility may able replace timely manner commercially reasonable terms problems single suppliers depend including event disaster earthquake equipment failure difficulty may negatively impact development commercialization efforts significant portion raw materials intermediates used manufacture antiviral products supplied thirdparty manufacturers corporate partners outside united states result political economic factors specific country region including changes interpretations trade regulations compliance requirements tax legislation would limit prevent third parties outside united states supplying materials would adversely affect ability manufacture supply antiviral products meet market needs material adverse effect operating results encounter difficulties ability provide products product candidates patients would jeopardized imports countries products available lower prices unapproved generic counterfeit versions products could negative impact reputation business prices products based local market economics competition sometimes differ country country sales countries relatively higher prices may reduced products imported countries lower price markets hiv hbv hcv products agreed make available substantially reduced prices certain low middleincome countries participating gilead access program exported low middleincome countries united states europe higher price markets revenues would adversely affected addition entered voluntary licensing agreements generic drug companies india south africa china well licensing agreement medicines patent pool united nationsbacked public health organization allows generic drug companies manufacture generic versions hiv hbv products incorporating licensed compounds taf cobicistat elvitegravir bictegravir distribution certain low middleincome countries also entered agreements generic manufacturers india egypt pakistan allowing produce andor distribute generic versions hcv products certain low middle income countries generic versions hiv hbv hcv products produced andor distributed agreements reexported united states europe markets outside low middleincome countries revenues would adversely affected addition purchases products countries selling prices relatively low resale countries selling prices relatively high may adversely impact revenues gross margin may cause sales fluctuate quarter quarter additionally use diverted products could occur countries approved patients could source product outside legitimate supply chain therefore products may handled shipped stored inappropriately may affect efficacy product could harm patients brands commercial scientific reputation products european union required permit products purchased one eu member state sold another eu member state purchases products countries selling prices relatively low resale countries selling prices relatively high affect inventory level held wholesalers cause relative sales levels various countries fluctuate quarter quarter reflect actual consumer demand given quarter quarterly fluctuations may impact earnings could adversely affect stock price harm business also aware existence various buyers clubs around world promote personal importation generic versions hcv hiv products approved use countries imported result patients may risk taking unapproved medications may purport may potency claim may contain harmful substances extent patients take unapproved generic versions one medications injured generic products brands commercial scientific reputation hcv hiv products could harmed third parties may illegally distribute sell counterfeit versions products meet rigorous quality standards manufacturing supply chain example reports product labeled epclusa available multiple countries determined authentic product based sample analysis lot number cooperated continue cooperate regulatory authorities investigate matter actively take actions discourage counterfeits products around world including working local regulatory legal authorities enforce laws counterfeit drugs raising public awareness dangers counterfeit drugs promoting public policies hinder sale availability counterfeit drugs counterfeit drugs pose serious risk patient health safety may raise risk product recalls reputation business could suffer result counterfeit drugs sold brand name expensive litigation government investigations increased expenses may continue reduce earnings involved number litigation investigation disputerelated matters require us expend substantial internal financial resources expect matters continue require high level internal financial resources foreseeable future matters reduced continue reduce earnings require significant management attention description litigation investigation disputerelated matters see note commitments contingencies notes consolidated financial statements included item annual report outcome legal proceedings legal proceedings may brought us investigations investigations may initiated disputerelated matters inherently uncertain adverse developments outcomes result significant expenses monetary damages penalties injunctive relief us could significantly reduce earnings cash flows harm business may face significant liability resulting products liability could materially reduce earnings testing manufacturing marketing use commercial products well product candidates development involve substantial risk product liability claims claims may made directly consumers healthcare providers pharmaceutical companies others limited insurance product liabilities may arise maintain adequate coverage claims exceed coverage financial condition adversely affected addition negative publicity associated claims regardless merit may decrease future demand products impair financial condition description products liability matters see note commitments contingencies notes consolidated financial statements included item annual report fail attract retain highly qualified personnel may unable successfully develop new product candidates conduct clinical trials commercialize product candidates future success depend large part continued ability attract retain highly qualified scientific technical management personnel well personnel expertise clinical testing governmental regulation commercialization face competition personnel companies universities public private research institutions government entities organizations competition qualified personnel biopharmaceutical field intense limited pool qualified potential employees recruit may able attract retain quality personnel acceptable terms additionally changes us immigration work authorization laws regulations could make difficult employees work transfer jurisdictions operations could impair ability attract retain qualified personnel unsuccessful recruitment retention efforts business may harmed end john f milligan stepped president chief executive officer following years service announced daniel p o'day serve chief executive officer effective march successfully manage transition new chief executive officer business may negatively impacted business disruptions natural manmade disasters may harm future revenues worldwide operations third party manufacturers corporate partners could subject business interruptions stemming natural manmade disasters including related climate change may uninsured inadequately insured corporate headquarters foster city santa monica location together house majority rd activities san dimas la verne oceanside el segundo manufacturing facilities located california seismically active region may carry adequate earthquake insurance significant recovery time could required resume operations financial condition operating results could materially adversely affected event major earthquake dependent information technology systems infrastructure data may subject cyberattacks security breaches dependent upon information technology systems infrastructure data including kite konnect platform critical ensure chain identity chain custody yescarta multitude complexity computer systems make inherently vulnerable service interruption destruction malicious intrusion random attack likewise data privacy security breaches employees others pose risk sensitive data including intellectual property trade secrets personal information employees patients customers business partners may exposed unauthorized persons public cyberattacks increasing frequency sophistication intensity cyberattacks could include deployment harmful malware denialofservice social engineering means affect service reliability threaten data confidentiality integrity availability business technology partners face similar risks security breach systems could adversely affect security posture invested continue invest protection data information technology infrastructure assurance efforts efforts partners vendors prevent service interruptions identify breaches systems interruptions breaches could adversely affect business operations andor cause loss critical sensitive information could result financial legal business reputational harm us addition insurance may sufficient type amount cover financial legal business reputational losses may result interruption breach systems regulators globally also imposing new data security requirements including greater monetary fines privacy violations example general data protection regulation gdpr became effective europe established new regulations regarding handling personal data noncompliance gdpr may result monetary penalties four percent worldwide revenue addition may subject additional data privacy security laws california consumer privacy act gdpr changes laws regulations associated enhanced protection certain types sensitive data including healthcare data personal information could greatly increase cost providing products services even prevent us offering certain services jurisdictions operate changes effective income tax rate could reduce earnings subject income taxes united states various foreign jurisdictions including ireland due economic political conditions various countries actively considering made changes existing tax laws predict form timing potential legislative regulatory changes could material adverse impact results operations example united states enacted significant tax reform certain provisions new law complex continue significantly affect us addition significant judgment required determining worldwide provision income taxes various factors may favorable unfavorable effects income tax rate including limited changes forecasted demand hcv products portion nontax deductible annual branded prescription drug fee accounting stock options sharebased awards mergers acquisitions ability manufacture product cork ireland facility amortization certain acquisition related intangibles receive tax benefit future levels rd spending changes mix earnings various tax jurisdictions operate changes overall levels pretax earnings resolution federal state foreign income tax audits potential changes legal entity structure impact income tax provision resulting mentioned factors may significant could negative impact consolidated results operations income tax returns subject audit federal state foreign tax authorities currently examination internal revenue service tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions resolution one exposures reporting period could material impact results operations period see note income taxes notes consolidated financial statements included item annual report additional details assurance pay dividends continue repurchase stock board directors authorized dividend program intend pay quarterly dividends per share subject quarterly declarations board directors board directors also approved repurchase billion common stock billion available repurchase december future declarations amount timing dividends andor amount timing stock repurchases subject capital availability determinations board directors cash dividends andor stock repurchases best interest stockholders compliance respective laws agreements applicable declaration payment cash dividends repurchase stock ability pay dividends andor repurchase stock depend upon among factors cash balances potential future capital requirements strategic transactions including acquisitions debt service requirements results operations financial condition factors beyond control board directors may deem relevant reduction elimination dividend payments dividend program andor stock repurchases could negative effect stock price item b unresolved staff comments applicable item properties corporate headquarters located foster city california house administrative manufacturing rd activities also rd facilities emeryville oceanside santa monica california gaithersburg maryland seattle washington edmonton alberta canada amsterdam netherlands manufacturing facilities el segundo la verne oceanside san dimas california alberta canada dublin cork ireland global operations include offices europe north america asia south america africa australia middle east believe existing properties including owned leased sites good condition suitable conduct business believe capital resources sufficient purchase lease construct additional facilities required meet expected longterm growth needs item legal proceedings description significant pending legal proceedings please see note commitments contingencies legal proceedings notes consolidated financial statements included item annual report incorporated herein reference item mine safety disclosures applicable part ii item market registrants common equity related stockholder matters issuer purchases equity securities common stock traded nasdaq global select market symbol gild february shares common stock outstanding held approximately stockholders record include shares held broker bank nominee performance graph following graph compares cumulative total stockholder return past five years two indices standard poors stock index sp index nasdaq biotechnology index nbi index stockholder return shown graph necessarily indicative future performance make endorse predictions future stockholder returns comparison cumulative total return investment past five years notes section soliciting material deemed filed sec incorporated reference filings securities act exchange act whether made date hereof irrespective general incorporation language filing shows cumulative return investment assuming investment common stock nbi index sp index december assuming dividends reinvested equity compensation plan information following table provides certain information respect equity compensation plans effect december number common shares remaining available issuance weightedaverage equity number common shares exercise price compensation plans issued upon exercise outstanding options excluding securities outstanding options warrants warrants rights reflected column rights b c plan category thousands dollars thousands equity compensation plans approved security holders equity incentive plan employee stock purchase plan total equity compensation plans approved security holders equity compensation plans approved security holders total notes take account million restricted stock stock unit awards performance share units phantom shares granted equity incentive plan employee stock purchase plan participants permitted purchase common stock discount certain dates payroll deductions within predetermined purchase period accordingly numbers determinable issuer purchases equity securities first quarter board directors authorized billion share repurchase program program repurchases may made open market privately negotiated transactions started repurchases program april repurchased retired million shares common stock billion open market transactions program table summarizes stock repurchase activity three months ended december maximum fair total number value shares total number average shares purchased may yet shares price paid part publicly purchased purchased per share announced program program thousands dollars thousands millions october october november november december december total notes difference total number shares purchased total number shares purchased part publicly announced program due shares common stock withheld us employee restricted stock unit awards order satisfy applicable tax withholding obligations item selected financial data gilead sciences inc selected consolidated financial data millions except per share data year ended december consolidated statement income data total revenues total costs expenses income operations provision income taxes net income net income attributable gilead net income per share attributable gilead common stockholders basic shares used per share calculation basic net income per share attributable gilead common stockholders diluted shares used per share calculation diluted cash dividends declared per share december consolidated balance sheet data cash cash equivalents marketable debt securities working capital total assets longterm obligations longterm debt including current portion retained earnings total stockholders equity notes see managements discussion analysis financial condition results operations included item annual report description results operations adopted accounting standards update topic revenue contracts customers using modified retrospective method applied contracts completed january results presented topic information prior periods adjusted continues reported accordance historical accounting topic revenue recognition impact result applying topic place topic material year ended december see note organization summary significant accounting policies note revenues notes consolidated financial statements included item annual report information december recorded estimated billion net charge related enactment tax cuts jobs act see note income taxes notes consolidated financial statements included item annual report additional details repaid billion principal amount senior unsecured notes maturity repaid billion term loans borrowed connection acquisition kite pharma inc kite fi c l c ri en ic gn ec et mio enn w oi ft wh hth ice h cq u bi li lo f w k asit e pw ae id insu ded ec em b e b r l li n aggregate principal amount senior unsecured notes registered offering drew billion aggregate principal amount term loan pin r n ci p l w bae l ais ns cu ee od f e n io b r ul nli en c rr ei dn c ni op ta el dm uo eu nt ef cs ee mn bio er r u n se c ured notes registered offering also repaid million principal balance convertible senior notes due may million issued billion principal amount senior unsecured notes registered offering also repaid million principal balance convertible senior notes due may bin l n ce w f se e ns ou ud n se c u rb ei dl l nio te p r din uc ei ip na l em co emun bt e ro f se n anr du n e c u r med il ln ioo nte us nin er g oi us rt e fir ed yo eff ae rr rn evg os l vw ine g l cs ro ed r ie tp fa ai cd il g rm ei el mli eo nn principal balance convertible senior notes due may million principal retrospectively adopted accounting standards update balance sheet classification deferred taxes requires deferred tax assets liabilities classified noncurrent balance sheet result reclassified deferred tax assets total current assets longterm assets deferred tax liabilities accrued liabilities longterm obligations years presented retrospectively adopted accounting standards update simplifying presentation debt issuance costs requires presentation debt issuance costs direct deduction carrying amount recognized debt liability balance sheet result reclassified unamortized debt issuance costs assets longterm debt including current portion years presented item managements discussion analysis financial condition results operations following managements discussion analysis financial condition results operations mda intended help reader understand results operations financial condition mda provided supplement read conjunction audited consolidated financial statements accompanying notes consolidated financial statements disclosures included annual report including disclosures part item risk factors consolidated financial statements prepared accordance us generally accepted accounting principles presented us dollars management overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatening illnesses around world operations countries worldwide headquarters foster city california gileads primary areas focus include hivaids liver diseases hematologyoncology inflammationrespiratory diseases seek add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategic collaborations portfolio marketed products includes ambisome atripla biktarvy cayston compleraeviplera descovy emtriva epclusa genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada tybost vemlidy viread vosevi yescarta zydelig also sell distribute certain products corporate partners collaborative agreements business highlights marked operational excellence transition positioned future growth business continued develop deliver innovative medicines help people lifethreatening illnesses around world highlights performance include hiv achieved record sales hiv products hiv product revenues increasing united states worldwide compared growth driven successful launch biktarvy continued strong uptake single tablet regimens containing tenofovir alafenamide taf treatment hiv infection well truvada preexposure prophylaxis prep indication hiv prevention biktarvy oncedaily single tablet regimen containing bictegravir emtricitabine ftc taf treatment hiv infection adults approved us food drug administration fda february european commission june liver diseases revenues chronic hepatitis c virus hcv products became predictable wanted introduce lower priced alternative hcv products without significant disruption healthcare system business authorized launch generic versions epclusa harvoni united states starting january separate subsidiary asegua therapeutics llc asegua also continued advance clinical trials treatment chronic hepatitis b virus hbv nonalcoholic steatohepatitis nash including completing enrollment phase clinical trials nash cell therapy immunooncology advanced pipeline cancer therapies positioned leader cell therapy yescarta approved european commission august treatment relapsed refractory diffuse large bcell lymphoma dlbcl primary mediastinal large bcell lymphoma pmbcl two lines systemic therapy certified additional centers united states europe provide treatment yescarta order advance accelerate research development efforts cell therapy immunooncology year entered key strategic collaborations national cancer institute pfizer inc pfizer sangamo therapeutics inc sangamo gadeta bv gadeta hifibio therapeutics hifibio tango therapeutics tango agenus inc agenus inflammation continued advance pipeline novel investigational agents inflammatory diseases including announcing positive data filgotinib ongoing phase clinical trials also entered strategic collaboration verily life sciences llc alphabet company verily using verilys immunoscape platform identify better understand immunological basis inflammatory diseases year continued invest advance research development pipeline across therapeutic areas end research development pipeline included active clinical studies phase clinical trials additionally completed collaborations partnerships strategic investments reflects commitment enabling access new technologies drug candidates potential evolve care people lifethreatening illnesses investments research development reflect commitment expanding pipeline across range diseases address areas significant unmet medical need positioning longterm growth business recent key announcements include hiv liver diseases programs fda european commission granted marketing authorization biktarvy treatment hiv infection fda approved truvada combination safer sex practices reduce risk sexually acquired hiv atrisk adolescents china national drug administration cda succeeded china national medical products administration nmpa approved genvoya china treatment hiv infection nmpa approved descovy china treatment hiv infection adults adolescents entered agreement japan tobacco inc japan tobacco expand rights develop commercialize elvitegravir include japan acquire japan tobacco rights market distribute certain products hiv portfolio japan effective january entered research collaboration license agreement hookipa biotech ag hookipa grants us exclusive rights hookipas therat vaxwave arenavirus vectorbased immunization technologies chronic hbv infection hiv infection announced plans launch authorized generic versions epclusa harvoni united states separate subsidiary asegua nmpa approved harvoni china treatment chronic hcv infection genotype adults adolescents aged years cda approved epclusa china treatment adults genotype chronic hcv infection cda also approved epclusa combination ribavirin adults chronic hcv infection decompensated cirrhosis nmpa approved vemlidy china treatment chronic hbv infection adults adolescents entered strategic collaboration precision biosciences precision develop therapies targeting vivo elimination chronic hbv infection precisions proprietary genome editing platform arcus announced stellar phase randomized doubleblind placebocontrolled study evaluating safety efficacy selonsertib investigational oncedaily oral inhibitor apoptosis signalregulating kinase ask patients compensated cirrhosis f due nash meet prespecified week primary endpoint stage histologic improvement fibrosis without worsening nash oncology cell therapy programs entered immunooncology partnership agenus focused development commercialization five novel immunooncology therapies entered global strategic collaboration tango discover develop commercialize pipeline targeted immunooncology treatments patients cancer european commission granted marketing authorization yescarta treatment adult patients relapsed refractory dlbcl pmbcl two lines systemic therapy announced new worldwide facilities advance manufacturing cell therapies people cancer entered research collaboration gadeta advance gamma delta cell receptor technology solid tumors collaboration adds additional new platform current capabilities research cell manufacturing entered research collaboration license agreement hifibio develop technology supporting discovery neoantigenreactive cell receptors potential treatment various cancers including solid tumors entered license agreement trianni inc trianni grants us use trianni transgenic human monoclonal antibody discovery platform support drug discovery efforts announced new cooperative research development agreement national cancer institute develop adoptive cell therapies targeting patientspecific tumor neoantigens entered worldwide collaboration sangamo using sangamos zinc finger nuclease technology platform development nextgeneration ex vivo cell therapies oncology entered clinical trial collaboration pfizer evaluate safety efficacy investigational combination yescarta pfizers utomilumab fully humanized bb agonist monoclonal antibody patients refractory large bcell lymphoma inflammation programs entered strategic collaboration scholar rock holding corporation discover develop highly specific inhibitors transforming growth factor beta activation treatment fibrotic diseases entered scientific collaboration verily using verilys immunoscape platform identify better understand immunological basis three common serious inflammatory diseases rheumatoid arthritis inflammatory bowel disease lupusrelated diseases transition following years service john f milligan phd stepped role president chief executive officer ceo effective december board announced selection daniel oday new chairman ceo effective march mr oday brings years executive management creative leadership operational excellence recently mr oday served ceo roche pharmaceuticals pharma division roche group leadership transitions throughout year resulting planned successions normal industry turnover financial highlights total revenues decreased billion total product sales decreased billion compared billion billion respectively primarily due lower sales hcv products partially offset higher sales hiv products united states product sales billion compared billion europe product sales billion compared billion product sales international locations billion compared billion cost goods sold increased billion compared billion primarily due reserves excess raw material inventory higher amortization related intangible assets acquired connection acquisition kite pharma inc kite inventory reserves million recorded excess raw materials primarily due sustained decrease demand harvoni result shift market harvoni epclusa research development rd expenses increased billion compared billion primarily due million impairment charge related inprocess rd iprd kite program antibcma evaluated treatment multiple myeloma increase upfront collaboration expenses enhance pipeline full year investments support growth business following acquisition kite higher stockbased compensation expenses associated acquisition kite selling general administrative sga expenses increased billion compared billion primarily due full year investments support growth business following acquisition kite partially offset lower acquisitionrelated costs associated acquisition kite lower branded prescription drug bpd fees net income attributable gilead billion per diluted share compared billion per diluted share increase primarily due billion charge income tax expense related enactment tax cuts jobs act tax reform recorded higher hiv product sales partially offset lower hcv product sales higher operating expenses associated advancement pipeline investments support growth business following acquisition kite december billion cash cash equivalents marketable debt securities compared billion december generated billion operating cash flow repaid billion principal amount debt paid cash dividends billion repurchased total million shares billion open market transactions outlook expect continue maintain strong focus operational excellence financial discipline rd perspective expect continue invest new ongoing clinical studies support existing products product candidates expect data readouts including selonsertib stellar treatment nash filgotinib treatment rheumatoid arthritis descovy prep indication order augment product pipeline continue pursue opportunities collaborations partnerships strategic investments fit long term strategic plan commercial perspective expect continue promote biktarvy hiv regimens containing taf addition believe truvada prep continue integral part growth hiv united states communities continue embrace public health benefits prevention hcv expect decline product sales result lower patient starts across markets competitive factors although lower rate believe launch authorized generic versions epclusa harvoni united states separate subsidiary asegua increase access medications patients lower prices cell therapy expect continue promote yescarta united states support launch europe continue help promote patient access products around world including gilead access program million people receive hiv medicines low middleincome countries progress initiatives subject number uncertainties including limited possibility unfavorable results new ongoing clinical trials example recently announced stellar phase study evaluating safety efficacy selonsertib patients compensated cirrhosis due nash meet prespecified week primary endpoint continuation uncertain global macroeconomic environment additional pricing pressures payers competitors slower anticipated growth hiv products increase discounts chargebacks rebates due ongoing contracts future negotiations commercial government payers market share price erosion caused introduction generic versions products containing tenofovir disoproxil fumarate tdf outside united states viread letairis ranexa united states inaccuracies hcv patient start estimates potential amendments affordable care act government action could effect lowering prices larger thananticipated shift payer mix highly discounted payer segment volatility foreign currency exchange rates results operations total revenues following table summarizes periodoverperiod changes product sales royalty contract revenues millions except percentages change change revenues product sales royalty contract revenues total revenues january adopted accounting standards update revenue contracts customers topic using modified retrospective method applied contracts completed january results presented topic information prior periods adjusted continues reported accordance historical accounting topic revenue recognition topic impact result applying topic place topic material year ended december see note organization summary significant accounting policies note revenues notes consolidated financial statements included item annual report information product sales compared total product sales decreased billion compared billion primarily due lower sales hcv products partially offset increased sales hiv products hiv product sales increased billion compared billion primarily due launch biktarvy continued uptake descovy genvoya odefsey hcv product sales decreased billion compared billion primarily due lower average net selling price lower sales volume across major markets result increased competition lower patient starts yescarta generated million sales compared million sales product sales include products hbv cardiovascular oncology categories inclusive vemlidy viread letairis ranexa zydelig ambisome decreased billion compared billion sales viread primarily used treatment chronic hbv infection decreased due availability generic versions product letairis expected face generic competition united states us patent ambrisentan active pharmaceutical ingredient letairis expired july ranexa also expected face generic competition united states expect decline letairis ranexa sales united states generic entries total product sales generated outside united states faced exposure movements foreign currency exchange rates primarily euro used foreign currency exchange contracts hedge percentage foreign currency exposure foreign currency exchange net hedges favorable impact product sales million compared record product sales net estimated mandatory supplemental discounts government payers addition discounts private payers including rebates chargebacks cash discounts prompt payment distributor fees related costs deductions generally referred grosstonet deductions totaled billion gross product sales compared billion gross products sales billion billion gross product sales related government rebates chargebacks billion related cash discounts prompt payment distributor fees related costs product sales united states decreased billion compared billion decrease primarily due lower sales hcv products partially offset higher sales hiv products decrease sales hcv products primarily due lower average net selling price lower sales volume result increased competition increase sales hiv products primarily due launch biktarvy continued uptake descovy genvoya odefsey increased usage truvada prep higher average net selling price partially offset decreases sales volume atripla complera stribild product sales europe decreased billion compared billion decrease primarily due lower sales hcv products availability generic versions truvada atripla viread decrease sales hcv products primarily due lower sales volume average net selling price result increased competition decrease partially offset launch biktarvy continued uptake descovy genvoya odefsey foreign currency exchange net hedges favorable impact product sales europe million compared product sales international locations decreased billion compared billion primarily due lower sales hcv products japan sales hcv products japan decreased million compared million primarily due lower market share result increased competition compared total product sales decreased billion compared billion primarily due lower sales hcv products partially offset increased sales hiv products hiv product sales increased billion compared billion primarily driven continued uptake descovy genvoya odefsey partially offset decreases sales truvada atripla complera stribild hcv product sales decreased billion compared billion primarily due declines across major markets result increased competition lower total market patient starts product sales include products hbv cardiovascular oncology categories inclusive vemlidy viread letairis ranexa zydelig ambisome increased billion compared billion total product sales generated outside united states faced exposure movements foreign currency exchange rates primarily euro used foreign currency exchange contracts hedge percentage foreign currency exposure foreign currency exchange net hedges unfavorable impact product sales million compared grosstonet deductions totaled billion gross product sales compared billion gross products sales billion billion gross product sales related government rebates chargebacks billion related cash discounts prompt payment distributor fees related costs product sales united states decreased billion compared billion declines sales hcv products partially offset increase sales hiv products declines sales hcv products primarily due lower harvoni sovaldi sales volume result increased competition lower total market patient starts additionally increases epclusa vosevi sales volume partially offset lower average net selling price epclusa pricing regimens gravitated towards week regimen price increase sales hiv products primarily due continued uptake descovy genvoya odefsey higher average net selling prices partially offset decreases truvada atripla complera stribild prior year favorable impact revision rebate reserves million primarily related truvada atripla complera stribild product sales europe decreased billion compared billion primarily due lower harvoni sovaldi sales volume partially offset higher epclusa sales volume foreign currency exchange net hedges unfavorable impact product sales europe million compared product sales international locations decreased billion compared billion primarily due lower sales japan sales hcv products japan decreased million compared billion primarily due lower sales volume result lower total market patient starts increased competition following table summarizes periodoverperiod changes product sales millions except percentages change change atripla biktarvy compleraeviplera descovy genvoya odefsey stribild truvada hiv revenue share symtuza total hiv ambisome epclusa harvoni letairis ranexa vemlidy viread vosevi yescarta zydelig total product sales notes percentage meaningful includes emtriva tybost represents revenue cobicistat c ftc taf symtuza darunavircftctaf fixed dose combination product commercialized janssen includes cayston hepsera sovaldi following additional discussion results certain products descovy ftctafbased products biktarvy descovy genvoya odefsey product sales descovy ftctafbased products billion billion billion total product sales respectively sales descovy ftctafbased products billion united states billion europe compared billion united states million europe billion united states million europe increase compared major markets primarily driven higher sales volume reflecting launch biktarvy continued uptake genvoya odefsey descovy increase compared major markets primarily driven higher sales volume patients shifted away truvada ftctdfbased regimens truvada ftctdfbased products atripla compleraeviplera stribild truvada product sales truvada ftctdfbased products billion billion billion total product sales respectively sales truvada ftctdfbased products billion united states million europe compared billion united states billion europe billion united states billion europe united states decrease compared primarily due lower sales volume result patients switching newer regimens containing taf partially offset increased usage truvada prep higher average net selling price certain truvada ftctdf based products europe decrease compared primarily due lower sales volume result availability generic versions truvada atripla patients switching newer regimens containing taf united states decrease compared primarily due lower sales volume result patients switching newer regimens containing taf partially offset increased usage truvada prep europe decreases compared primarily due lower sales volume result availability generic versions truvada several countries patients switching newer regimens containing taf hcv products epclusa harvoni sovaldi vosevi hcv product sales billion billion billion total product sales respectively sales hcv products billion united states million europe million international locations sales hcv products billion united states billion europe billion international locations sales hcv products billion united states billion europe billion international locations decrease compared major markets primarily due lower sales volume lower average net selling price result increased competition lower total market patient starts harvoni sovaldi product sales also decreased result shift market harvoni sovaldi epclusa decrease compared major markets primarily due lower sales volume lower average net selling price result increased competition lower total market patient starts harvoni sovaldi product sales also decreased result shift market harvoni sovaldi epclusa epclusa product sales increased compared primarily due full year sales epclusa approved fda european commission june july respectively cost goods sold product gross margin following table summarizes periodoverperiod changes product sales cost goods sold product gross margin millions except percentages change change total product sales cost goods sold product gross margin cost goods sold increased million compared primarily due higher inventory reserves recorded inventory reserves million million related excess raw materials primarily due sustained decrease demand harvoni result shift market harvoni epclusa inventory reserves recorded years ended december material cost goods sold also increased due full year amortization expense related intangible assets acquired connection acquisition kite october increases partially offset lower costs efavirenz component atripla result termination collaboration arrangement bristolmyers squibb company december decrease product gross margin compared primarily due factors impacting cost goods sold noted changes product mix decrease product gross margin compared primarily due changes product mix hcv product sales decreased percentage total product sales research development expenses following table summarizes periodoverperiod changes rd expenses millions except percentages change change rd expenses rd expenses consist primarily clinical studies performed contract research organizations materials supplies licenses fees upfront milestone payments collaboration agreements personnel costs including salaries benefits stockbased compensation overhead allocations consisting various support facilitiesrelated costs track total rd expenses product candidate therapeutic area development phase however manage rd expenses identifying rd activities anticipate performed given period prioritizing efforts based scientific data probability successful development market potential available human capital resources considerations continually review rd pipeline status development necessary reallocate resources among rd portfolio believe best support future growth business following table provides breakout rd expenses major cost type millions clinical studies outside services personnel infrastructure expenses iprd impairment charges upfront collaboration expenses acquired iprd stockbased compensation expenses total rd expenses increased billion compared primarily due million impairment charge related iprd kite program due discontinuance increase upfront collaboration expenses higher personnel facilitiesrelated costs support growth business following acquisition kite partially offset higher acquired iprd expense result purchase cell design labs inc rd expenses decreased billion compared primarily due impacts business development activities resulting front collaboration expense related license collaboration agreement galapagos nv acquired iprd expense related purchase nimbus apollo inc iprd impairment charges ongoing milestone payments partially offset acquired iprd expense related purchase cell design labs inc selling general administrative expenses following table summarizes periodoverperiod changes sga expenses millions except percentages change change sga expenses sga expenses relate sales marketing finance human resources legal administrative activities expenses consist primarily personnel costs facilities overhead costs outside marketing advertising legal expenses general administrative costs sga expenses also include bpd fee united states along pharmaceutical manufacturers branded drug products required pay portion bpd fee estimated based select government sales prior year percentage total industry government sales truedup upon receipt invoices internal revenue service sga expenses increased million compared primarily due full year expense support growth business following acquisition kite partially offset lower acquisitionrelated costs associated acquisition kite lower bpd fees sga expenses increased million compared primarily due costs associated acquisition kite primarily consist stockbased compensation transaction costs well higher bpd fee expenses resulting favorable adjustment million first quarter bpd fee expenses million million million respectively bpd fee expenses taxdeductible income expense net income expense net million million million respectively increase compared primarily due unrealized gains changes fair value marketable equity securities starting january recorded unrealized gains losses changes fair value marketable equity securities income expense net consolidated statements income result adoption accounting standards update financial instrumentsoverall recognition measurement financial assets financial liabilities see note organization summary significant accounting policies notes consolidated financial statements included item annual report information increase income expense net compared primarily due cash cash equivalents marketable securities earning higher yield higher cash balances provision income taxes provision income taxes billion compared billion effective tax rate decreased effective tax rate primarily due billion net tax charge reduction us corporate tax rate result enactment tax reform december addition effective tax rate decreased due million tax benefit recorded related settlement tax examinations offset million deferred tax charge resulting transfer acquired intangible assets wholly owned subsidiaries changes geographic mix earnings tax global intangible lowtaxed income enacted part tax reform continuing evaluate certain changes legal entity structure response guidelines requirements various international tax jurisdictions conduct business changes may take multiple reporting periods implement may result certain material nonrecurring adjustments deferred tax assets andor liabilities cause offsetting increase decrease tax provision estimates adjustments reasonably determined time dependent changes actually implemented provision income taxes billion compared billion effective tax rate increased effective tax rate primarily due enactment tax reform december changes geographic mix earnings also contributed increase effective tax rate see note income taxes notes consolidated financial statements included item annual report additional details tax reform liquidity capital resources following table summarizes cash cash equivalents marketable debt securities working capital millions december cash cash equivalents marketable debt securities working capital cash cash equivalents marketable debt securities cash cash equivalents marketable debt securities decreased billion compared december generated billion operating cash flow repaid billion principal amount senior unsecured notes maturity repaid billion term loans borrowed connection acquisition kite paid cash dividends billion utilized billion stock repurchases working capital working capital increased billion compared december primarily driven increase cash cash equivalents resulting shift average remaining term maturity marketable debt securities portfolio reduce interest rate risk cash flows following table summarizes cash flow activities millions cash provided used operating activities investing activities financing activities cash provided operating activities cash provided operating activities represents cash receipts disbursements related activities investing financing activities operating cash flow derived adjusting net income noncash items changes operating assets liabilities cash provided operating activities decreased billion billion compared primarily due lower cash receipts result lower product sales higher tax payments tax payments made included million payment related first annual installment tax reform transition tax million deemed early payment tax reform transition tax million settlement tax examination cash provided operating activities decreased billion billion compared primarily due lower cash receipts result lower product sales higher tax payments cash provided used investing activities cash provided used investing activities primarily consists purchases sales maturities marketable debt securities capital expenditures acquisitions net cash acquired investments cash provided investing activities billion compared cash used investing activities billion change cash provided used investing activities primarily due higher proceeds maturities marketable debt securities lower purchases marketable debt securities partially offset lower proceeds sales marketable debt securities addition billion cash used acquire kite whereas cash used acquisitions cash used investing activities increased billion billion compared primarily due acquisition kite partially offset higher proceeds maturities sales marketable debt securities lower purchases marketable debt securities cash provided used financing activities cash used financing activities billion compared cash provided financing activities billion change cash provided used financing activities primarily due higher repayment debt repurchases common stock addition billion net proceeds debt issuances partially fund acquisition kite whereas debt issued cash provided financing activities billion compared cash used financing activities billion primarily due lower repurchases common stock higher proceeds issuances debt debt credit facilities longterm obligations summary borrowings various financing arrangements included note debt credit facilities notes consolidated financial statements included item annual report senior unsecured notes repaid maturity billion principal amount senior unsecured notes issued september million principal amount senior unsecured notes issued september connection acquisition kite issued billion aggregate principal amount senior unsecured notes consisting million principal amount floating rate notes due september million principal amount floating rate notes due march million principal amount floating rate notes due september collectively floating rate notes billion principal amount senior notes due september fixed rate notes collectively floating rate notes notes floating rate notes bear interest rates equal three month london interbank offered rates libor plus respect floating rate notes due september respect floating rate notes due march respect floating rate notes due september fixed rate notes pay interest semiannually floating rate notes pay interest quarterly required comply certain covenants notes indentures december violation covenants term loan facilities september entered billion aggregate principal amount term loan facility credit agreement consisting billion principal amount day senior unsecured term loan facility billion principal amount threeyear senior unsecured term loan facility billion principal amount fiveyear senior unsecured term loan facility collectively term loan facilities october drew billion aggregate principal amount term loan facilities used proceeds finance acquisition kite billion repaid remaining billion repaid term loan facility credit agreement terminated credit facilities entered billion fiveyear revolving credit facility maturing may fiveyear revolving credit agreement revolving credit facility used working capital requirements general corporate purposes including without limitation acquisitions required comply certain covenants fiveyear revolving credit agreement december violation covenants amounts outstanding fiveyear revolving credit agreement capital return program details stock repurchase programs dividends included note stockholders equity notes consolidated financial statements included item annual report additional information stock repurchase programs first quarter board directors authorized billion stock repurchase program program repurchases may made open market privately negotiated transactions started repurchases program april repurchases program million million shares common stock billion million respectively december remaining authorized repurchase amount program billion dividends declared paid quarterly cash dividends aggregate amount billion per common share billion per common share respectively february announced board directors declared quarterly cash dividend increase per share common stock payment date march stockholders record close business march future dividends subject declaration board directors capital resources believe existing capital resources supplemented cash flows generated operations adequate satisfy capital needs foreseeable future future capital requirements depend many factors including limited following commercial performance current future products progress scope rd efforts including preclinical studies clinical trials cost timing outcome regulatory reviews expansion sales marketing capabilities possibility acquiring additional manufacturing capabilities office facilities possibility acquiring companies new products debt service requirements establishment additional collaborative relationships companies costs associated defense settlement adverse results government investigations litigation may future require additional funding could form proceeds equity debt financings funding required guarantee available us favorable terms critical accounting policies estimates judgments discussion analysis financial condition results operations based consolidated financial statements included item annual report prepared accordance us generally accepted accounting principles preparation financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates believe following critical accounting policies reflect significant judgments estimates used preparation consolidated financial statements revenue recognition adoption asc topic revenue contracts customers january adopted topic using modified retrospective method whereby results reporting periods beginning january presented topic prior period amounts adjusted continue reported accordance historical accounting topic topic entity recognizes revenue transfers control promised goods services customers amount reflects consideration entity expects entitled exchange goods services recorded cumulative effect applying new revenue standard net increase million opening balance retained earnings impact result applying topic place topic material year ended december product sales recognize revenue product sales control product transfers generally upon shipment delivery customer certain cases upon corresponding sales customer third party record product sales net estimated mandatory supplemental discounts government private payers addition discounts private payers related charges generally accounted variable consideration estimated period related sales occur government rebates chargebacks represent majority variable consideration require complex significant judgment management estimates assessed period updated reflect current information government rebates chargebacks government rebates chargebacks include amounts paid payers healthcare providers united states including medicaid rebates aids drug assistance program rebates chargebacks veterans administration public health service chargebacks rebates well foreign government rebates rebates chargebacks based contractual arrangements statutory requirements may vary product payer individual payer plans qualified programs purchase products wholesalers distributors lower contractual price wholesalers distributors charge back us difference acquisition cost lower contractual price allowances government rebates chargebacks estimated based products sold historical payer mix pertinent thirdparty industry information estimated patient population known market events trends channel inventory data andor market data also consider new information regarding changes programs regulations guidelines would impact amount actual rebates andor expectations regarding future payer mix programs believe methodology use estimate government rebates chargebacks reasonable appropriate given current facts circumstances however actual results may differ significantly estimates historically actual government rebates chargebacks claimed prior periods varied less estimates government chargebacks payable direct customers classified reductions accounts receivable consolidated balance sheets totaled million million december respectively government rebates invoiced directly us recorded accrued government rebates consolidated balance sheets totaled billion billion december respectively following table summarizes consolidated activities ending balances government rebates chargebacks accounts millions balance decreaseincrease balance end accrued government rebates chargebacks beginning year product sales payments year year ended december activity related sales activity related sales prior total year ended december activity related sales activity related sales prior total legal contingencies party various legal actions significant described note commitments contingencies legal proceedings notes consolidated financial statements included item annual report possible determine outcome matters recognize accruals actions extent conclude loss probable reasonably estimable accrue best estimate loss within range however estimate range better accrue minimum amount range determine loss reasonably possible loss range loss estimated disclose possible loss significant judgment required determination probability determination whether exposure reasonably estimable inherent uncertainty unpredictability related matters accruals based believe best information available time assessment including legal facts circumstances case status proceedings applicable law views legal counsel upon final resolution matters possible may loss excess amount recorded amounts could material adverse effect results operations cash flows financial position periodically reassess matters additional information becomes available adjust estimates assumptions facts circumstances indicate need changes recognize accruals consolidated balance sheets matters december believe losses probable valuation intangible assets identifiable intangible assets measured respective fair values acquisition date may subject revision within measurement period may one year acquisition date models used valuing intangible assets require use significant estimates assumptions including limited estimates revenues operating profits related products product candidates probability success unapproved product candidates considering stages development time resources needed complete development approval product candidates life potential commercialized products associated risks including inherent difficulties uncertainties developing product candidate obtaining fda regulatory approvals risks related viability potential alternative treatments future target markets believe fair values used record intangible assets acquired connection business combination using information known knowable based upon reasonable estimates assumptions given facts circumstances related valuation dates intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts development complete generally occurs regulatory approval market product obtained associated assets would deemed finitelived would amortized based respective estimated useful lives point time period assets considered indefinite lived amortized tested impairment annual basis well annual tests become aware events changes would indicate likely fair values iprd projects respective carrying amounts fair value indefinite lived intangible assets dependent assumptions expected timing probability achieving specified milestones changes projected revenues changes discount rates significant judgment employed determining assumptions changes assumptions could significant impact results operations given period intangible assets finite useful lives amortized estimated useful lives primarily straightline basis intangible assets finite useful lives reviewed impairment facts circumstances suggest carrying value assets may recoverable october connection kite acquisition acquired intangible assets primarily related iprd axicabtagene ciloleucel kite antibcma evaluated treatment multiple myeloma ktex evaluated treatment adult pediatric acute lymphoblastic leukemia estimated aggregate fair value billion october fda approved axicabtagene ciloleucel known commercially yescarta making first car cell therapy treatment adult patients relapsed refractory large bcell lymphoma two lines systemic therapy includes diffuse large bcell lymphoma transformed follicular lymphoma primary mediastinal bcell lymphoma upon approval reclassified billion purchased iprd finitelived intangible asset amortizing asset estimated useful life years using straightline method fourth quarter concluded efficacy profile kite program justify efforts based totality clinical data gathered made decision discontinue kite program result estimated fair value iprd relating kite program written zero recorded impairment charge million within research development expenses consolidated statements income included item annual report provision income taxes estimate income tax provision including deferred tax assets liabilities based significant management judgment evaluate realization portion deferred tax assets quarterly basis record valuation allowance reduce deferred tax assets amounts likely realized consider future taxable income ongoing tax planning strategies historical financial performance assessing need valuation allowance expect realize deferred tax assets previously recorded valuation allowance reduce valuation allowance period determination first made valuation allowance million million december respectively increase valuation allowance primarily related certain kite tax attributes certain foreign jurisdictions sufficient history profit realize benefit losses morelikelythannot basis subject income taxes united states various foreign jurisdictions including ireland due economic political conditions various countries actively considering made changes existing tax laws example united states enacted significant tax reform certain provisions new law continue significantly affect us predict form timing potential legislative changes could material adverse impact results operations addition significant judgment required determining worldwide provision income taxes record liabilities related uncertain tax positions accordance guidance clarifies accounting uncertainty income taxes recognized enterprises financial statements prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return adverse resolution one uncertain tax positions period could material impact results operations period total unrecognized tax benefits billion billion december recognized would reduce effective tax rate period recognition december believe reasonably possible unrecognized tax benefits decrease approximately million next months due potential settlements taxing authorities file federal state foreign income tax returns united states many foreign jurisdictions federal income tax purposes statute limitations open onwards onwards california income tax purposes certain acquired entities statute limitations open years inception due utilization net operating losses credits carried prior years income tax returns subject audit federal state foreign tax authorities currently examination irs tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions see note income taxes notes consolidated financial statements included item annual report additional information balance sheet arrangements balance sheet arrangements defined item aii regulation sk contractual obligations contractual obligations consist debt obligations operating leases capital commitments purchase obligations active pharmaceutical ingredients inventoryrelated items clinical trials contracts following table summarizes significant enforceable legally binding obligations future commitments obligations related contracts likely continue regardless fact certain obligations may cancelable december millions payments due period less one contractual obligations total year years years years debt operating lease obligations capital commitments purchase obligations clinical trials transition tax payable total notes debt consists senior unsecured notes includes principal interest payments interest payments fixed rate senior unsecured notes incurred calculated based terms related notes interest payments variable rate debt calculated based interest rates last reset date debt instrument see note debt credit facilities notes consolidated financial statements included item annual report additional information amounts include capital project commitments primarily relating construction new buildings amounts include purchase commitments primarily relating active pharmaceutical ingredients minimum purchase requirements certain inventoryrelated items amounts also include million accrued payment japan tobacco inc result collaboration arrangement see note collaborative arrangements notes consolidated financial statements included item annual report additional information addition committed make potential future milestone payments third parties part licensing collaboration development arrangements payments agreements generally become due payable upon achievement certain developmental regulatory andor commercial milestones achievement milestones neither probable reasonably estimable contingencies recorded consolidated balance sheets included table december several clinical studies various clinical trial phases significant clinical trial expenditures contract research organizations cros although material contracts cros cancelable historically canceled contracts amounts reflect commitments based existing contracts reflect future modifications terminations existing contracts anticipated potential new contracts connection tax reform december recorded federal income tax payable transition tax mandatory deemed repatriation foreign earnings payable eightyear period amounts included table represent remaining federal income tax payable applying first years installment payment early payments future installments see note income taxes notes consolidated financial statements included item annual report form k additional details tax reform december longterm income taxes payable includes unrecognized tax benefits interest penalties totaling billion due high degree uncertainty timing future cash settlement events could extinguish unrecognized tax benefits unable estimate period cash settlement therefore excluded unrecognized tax benefits table recent accounting pronouncements information required item included note organization summary significant accounting policies notes consolidated financial statements included item annual report item quantitative qualitative disclosures market risk exposed market risks may result changes foreign currency exchange rates interest rates credit risks market price reduce certain risks enter various types foreign currency interest rate derivative hedging transactions follow investment guidelines monitor outstanding receivables part risk management program foreign currency exchange risk operations include manufacturing sales activities united states canada ireland well sales activities countries outside united states including europe asia pacific result financial results could significantly affected factors changes foreign currency exchange rates weak economic conditions foreign markets distribute products operating results exposed changes foreign currency exchange rates us dollar various foreign currencies significant euro us dollar strengthens currencies relative value sales made respective foreign currency decreases conversely us dollar weakens currencies relative amounts sales increase overall net receiver foreign currencies therefore benefit weaker us dollar adversely affected stronger us dollar relative foreign currencies transact significant amounts business approximately product sales denominated foreign currencies partially mitigate impact changes currency exchange rates net cash flows foreign currency denominated sales may enter foreign currency exchange forward option contracts also hedge certain monetary assets liabilities denominated foreign currencies reduces eliminate exposure currency fluctuations date transaction recorded date cash collected paid general market risks contracts offset corresponding gains losses transactions hedged december open foreign currency forward contracts notional amounts billion billion respectively hypothetical adverse movement foreign currency exchange rates compared us dollar relative exchange rates december would resulted reduction fair value contracts approximately million date realized would negatively affect earnings remaining life contracts hypothetical movement foreign currency exchange rates compared us dollar relative exchange rates december would resulted reduction fair value contracts approximately million date realized would negatively affect earnings remaining life contracts analysis consider impact hypothetical changes foreign currency exchange rates would anticipated transactions foreign currency sensitive instruments designed offset interest rate risk portfolio availableforsale marketable debt securities fixed variable rate liabilities create exposure interest rate risk respect investment portfolio adhere investment policy requires us limit amounts invested securities based credit rating maturity industry group investment type issuer except securities issued us government goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return following table summarizes expected maturities average interest rates interestgenerating assets interestbearing liabilities december millions except percentages expected maturity total fair thereafter total value assets availableforsale debt securities average interest rate liabilities longterm debt including current portion fixed rate average interest rate variable rate average interest rate notes amounts represent principal balances addition fixed variable rate longterm debt billion fiveyear revolving credit facility amounts outstanding fiveyear revolving credit facility december see note debt credit facilities notes consolidated financial statements included item annual report additional information average interest rates variable rate debt based interest rates last reset date debt instrument dependent upon several factors subject change including limited libor principal amount debt outstanding credit ratings reset date credit risk subject credit risk portfolio cash equivalents marketable debt securities investment policy limit amounts invested securities credit rating maturity industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales majority trade accounts receivable arises product sales united states europe december accounts receivable net southern europe specifically greece italy portugal spain totaled approximately million million greater days past due including million greater days past due december accounts receivable net southern europe specifically greece italy portugal spain totaled approximately million million greater days past due including million greater days past due date experienced significant losses respect collection accounts receivable market price risk hold shares common stock certain publicly traded biotechnology companies connection license collaboration agreements equity securities measured fair value changes fair value recognized earnings starting january result adoption accounting standards update financial instrumentsoverall recognition measurement financial assets financial liabilities see note organization summary significant accounting policies notes consolidated financial statements included item annual report information fair value equity securities approximately million million december respectively changes fair value equity securities primarily due volatility stock market changes general economic conditions among factors hypothetical increase decrease stock prices equity securities would increase decrease fair value december approximately million million respectively item financial statements supplementary data gilead sciences inc index consolidated financial statements supplementary data years ended december contents report independent registered public accounting firm audited consolidated financial statements consolidated balance sheets consolidated statements income consolidated statements comprehensive income consolidated statements stockholders equity consolidated statements cash flows notes consolidated financial statements selected quarterly financial information unaudited schedule ii valuation qualifying accounts report independent registered public accounting firm shareholders board directors gilead sciences inc opinion financial statements audited accompanying consolidated balance sheets gilead sciences inc company december related consolidated statements income comprehensive income stockholders equity cash flows three years period ended december related notes financial statement schedule listed index item collectively referred consolidated financial statements opinion consolidated financial statements present fairly material respects financial position company december results operations cash flows three years period ended december conformity us generally accepted accounting principles also audited accordance standards public company accounting oversight board united states pcaob companys internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework report dated february expressed unqualified opinion thereon basis opinion financial statements responsibility companys management responsibility express opinion companys financial statements based audits public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audits accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether financial statements free material misstatement whether due error fraud audits included performing procedures assess risks material misstatement financial statements whether due error fraud performing procedures respond risks procedures included examining test basis evidence regarding amounts disclosures financial statements audits also included evaluating accounting principles used significant estimates made management well evaluating overall presentation financial statements believe audits provide reasonable basis opinion ernst young llp served companys auditor since san jose california february gilead sciences inc consolidated balance sheets millions except per share amounts december assets current assets cash cash equivalents shortterm marketable securities accounts receivable net allowances respectively inventories prepaid current assets total current assets property plant equipment net longterm marketable securities intangible assets net goodwill longterm assets total assets liabilities stockholders equity current liabilities accounts payable accrued government rebates accrued liabilities current portion longterm debt obligations net total current liabilities longterm debt net longterm income taxes payable longterm obligations commitments contingencies note stockholders equity preferred stock par value per share shares authorized none outstanding common stock par value per share authorized shares issued outstanding respectively additional paidin capital accumulated comprehensive income retained earnings total gilead stockholders equity noncontrolling interest total stockholders equity total liabilities stockholders equity see accompanying notes gilead sciences inc consolidated statements income millions except per share amounts year ended december revenues product sales royalty contract revenues total revenues costs expenses cost goods sold research development expenses selling general administrative expenses total costs expenses income operations interest expense income expense net income provision income taxes provision income taxes net income net income loss attributable noncontrolling interest net income attributable gilead net income per share attributable gilead common stockholders basic shares used per share calculation basic net income per share attributable gilead common stockholders diluted shares used per share calculation diluted see accompanying notes gilead sciences inc consolidated statements comprehensive income millions year ended december net income comprehensive income loss net foreign currency translation gain loss net tax availableforsale securities net unrealized gain net tax impact respectively reclassifications net income loss net tax impact respectively net change cash flow hedges net unrealized gain loss net tax impact respectively reclassification net income net tax impact respectively net change comprehensive income loss comprehensive income comprehensive income loss attributable noncontrolling interest comprehensive income attributable gilead see accompanying notes gilead sciences inc consolidated statements stockholders equity millions except per share amounts gilead stockholders equity common stock accumulated additional total paidin comprehensive retained noncontrolling stockholders shares amount capital income loss earnings interest equity balance december change noncontrolling interest net income loss comprehensive income net tax issuances employee stock purchase plan issuances equity incentive plans tax benefits employee stock plans stockbased compensation repurchases common stock warrants settlement convertible notes settlement convertible note hedges settlement dividends declared per share reclassification conversion spread convertible notes reclassification convertible note hedges reclassification equity component currently redeemable convertible notes balance december change noncontrolling interest net income comprehensive loss net tax issuances employee stock purchase plan issuances equity incentive plans stockbased compensation repurchases common stock dividends declared per share balance december change noncontrolling interest net income comprehensive income net tax issuances employee stock purchase plan issuances equity incentive plans stockbased compensation repurchases common stock dividends declared per share cumulative effect adoption new accounting standards balance december see accompanying notes gilead sciences inc consolidated statements cash flows millions year ended december operating activities net income adjustments reconcile net income net cash provided operating activities depreciation expense amortization expense stockbased compensation expense deferred income taxes inprocess research development impairment inventory reserves excess raw materials changes operating assets liabilities accounts receivable net inventories prepaid expenses accounts payable income taxes payable accrued liabilities net cash provided operating activities investing activities purchases marketable securities proceeds sales marketable securities proceeds maturities marketable securities investments acquisitions net cash acquired capital expenditures net cash provided used investing activities financing activities proceeds debt financing net issuance costs proceeds convertible note hedges proceeds issuances common stock repurchases common stock repayments debt obligations payments settle warrants payment dividends net cash provided used financing activities effect exchange rate changes cash cash equivalents net change cash cash equivalents cash cash equivalents beginning period cash cash equivalents end period supplemental disclosure cash flow information interest paid net amounts capitalized income taxes paid see accompanying notes gilead sciences inc notes consolidated financial statements organization summary significant accounting policies overview gilead sciences inc gilead us incorporated delaware june researchbased biopharmaceutical company discovers develops commercializes innovative medicines areas unmet medical need new discovery investigational drug candidate strive transform simplify care people lifethreatening illnesses around world operations countries worldwide headquarters foster city california gileads primary areas focus include hivaids liver diseases hematologyoncology inflammationrespiratory diseases seek add existing portfolio products internal discovery clinical development programs product acquisition inlicensing strategic collaborations portfolio marketed products includes ambisome atripla biktarvy cayston compleraeviplera descovy emtriva epclusa genvoya harvoni hepsera letairis odefsey ranexa sovaldi stribild truvada tybost vemlidy viread vosevi yescarta zydelig also sell distribute certain products corporate partners collaborative agreements basis presentation accompanying consolidated financial statements include accounts gilead whollyowned subsidiaries certain variable interest entities primary beneficiary intercompany transactions eliminated consolidated entities exposed less economics record net income loss attributable noncontrolling interests consolidated statements income equal percentage economic ownership interest retained entities respective noncontrolling parties assess whether primary beneficiary variable interest entity vie inception arrangement reporting date assessment based power direct activities vie significantly impact vies economic performance obligation absorb losses right receive benefits vie could potentially significant vie december material vies significant accounting policies estimates judgments preparation consolidated financial statements requires us make estimates judgments affect reported amounts assets liabilities revenues expenses related disclosures ongoing basis evaluate significant accounting policies estimates base estimates historical experience various market specific relevant assumptions believe reasonable circumstances results form basis making judgments carrying values assets liabilities readily apparent sources actual results may differ significantly estimates revenue recognition january adopted accounting standards update revenue contracts customers topic using modified retrospective method topic supersedes revenue recognition requirements topic revenue recognition topic result changed accounting policies revenue recognition detailed policy elections practical expedients taken account shipping handling activities performed customer obtained control good fulfillment costs rather separate performance obligations expect contract inception period transfer control corresponding payment customer one year less adjust amount consideration effects significant financing component product sales recognize revenue product sales control product transfers generally upon shipment delivery customer certain cases upon corresponding sales customer third party upon recognition revenue product sales provisions made various forms variable consideration include government rebates medicaid reimbursements customer incentives cash discounts prompt payment distributor fees expected returns expired products appropriate payment terms customers generally range days variable consideration rebates chargebacks estimate reductions revenues amounts paid payers healthcare providers united states including medicaid rebates aids drug assistance program rebates chargebacks veterans administration public health service chargebacks rebates well foreign government rebates rebates chargebacks based contractual arrangements statutory requirements may vary product payer individual payer plans estimates based products sold historical payer mix available pertinent thirdparty industry information estimated patient population known market events trends us product sales channel inventory data obtained major us wholesalers accordance inventory management agreements also take consideration available new information regarding changes programs regulations guidelines would impact amount actual rebates andor expectations regarding future payer mix programs government chargebacks payable direct customers classified reductions accounts receivable consolidated balance sheets government rebates invoiced directly us recorded accrued government rebates consolidated balance sheets cash discounts estimate cash discounts based contractual terms historical customer payment patterns expectations regarding future customer payment patterns distributor fees inventory management agreements significant us wholesalers pay wholesalers fee primarily compliance certain contractually determined covenants maintenance agreed upon inventory levels distributor fees based contractually determined fixed percentage sales product returns provide customers general right product return typically permit returns product damaged defective otherwise used received customer case product sold united states certain countries product expired accept returns product expire within six months expired one year expiration dates estimates expected returns expired products based primarily ongoing analysis historical return patterns historical industry information reporting return rates similar products contractual agreements intended limit amount inventory maintained wholesalers royalty contract revenues royalty revenue recognized period obligation satisfied corresponding sales corporate partners occur research development expenses research development rd expenses consist primarily personnel costs including salaries benefits stockbased compensation clinical studies performed contract research organizations cros materials supplies licenses fees upfront milestone payments collaboration arrangements overhead allocations consisting various support facilityrelated costs charge rd costs including clinical study costs expense incurred clinical study costs significant component rd expenses clinical studies performed thirdparty cros monitor levels performance significant contract including extent patient enrollment activities communications cros accrue costs clinical studies performed cros service periods specified contracts adjust estimates required based upon ongoing review level effort costs actually incurred cros material cro contracts terminable us upon written notice generally liable actual services completed cro certain noncancelable expenses incurred point termination selling general administrative expenses selling general administrative sga expenses relate sales marketing finance human resources legal administrative activities sga expenses consist primarily personnel costs facilities overhead costs outside marketing advertising legal expenses general administrative costs sga expenses also include branded prescription drug fee expense costs advertising including promotional expenses incurred advertising expenses million million million years ended december respectively cash cash equivalents consider highly liquid investments insignificant interest rate risk original maturity three months less purchase date cash equivalents marketable nonmarketable securities marketable debt securities determine appropriate classification marketable debt securities time purchase reevaluate designation balance sheet date marketable debt securities considered availableforsale carried estimated fair values reported cash equivalents shortterm marketable securities longterm marketable securities unrealized gains losses availableforsale debt securities excluded net income reported accumulated comprehensive income loss aoci separate component stockholders equity income expense net includes interest dividends amortization purchase premiums discounts realized gains losses sales securities otherthantemporary declines fair value securities cost securities sold based specific identification method regularly review investments otherthantemporary declines fair value review includes consideration cause impairment including creditworthiness security issuers number securities unrealized loss position severity duration unrealized losses whether intent sell securities whether likely required sell securities recovery amortized cost basis determine decline fair value investment accounting basis decline otherthantemporary reduce carrying value security hold record loss amount decline marketable nonmarketable equity securities investments equity securities equity method investments recorded fair market value fair value readily determinable equity securities readily determinable fair values recorded using measurement alternative cost less impairment adjusted observable price changes orderly transactions identical similar investments issuer certain investments equity securities nonpublic companies accounted using equity method based ownership percentage factors indicate significant influence investee investments equity securities recorded prepaid current assets long term assets consolidated balance sheet unrealized gains losses recorded part income expense net regularly review securities indicators impairment investments nonpublic companies material periods presented concentrations risk subject credit risk portfolio cash equivalents marketable securities investment policy limit amounts invested securities credit rating maturity industry group investment type issuer except securities issued us government exposed significant concentrations credit risk financial instruments goals investment policy order priority follows safety preservation principal diversification risk liquidity investments sufficient meet cash flow requirements competitive aftertax rate return also subject credit risk accounts receivable related product sales majority trade accounts receivable arises product sales united states europe japan date experienced significant losses respect collection accounts receivable believe allowance doubtful accounts adequate december certain raw materials components utilize operations obtained single suppliers certain raw materials utilize operations made one facility since suppliers key components raw materials must named new drug application filed us food drug administration fda product significant delays occur qualification new supplier required delivery material suppliers interrupted reason may unable ship commercial products supply product candidates clinical trials accounts receivable trade accounts receivable recorded net allowances wholesaler chargebacks related government programs cash discounts prompt payment doubtful accounts estimates wholesaler chargebacks government programs cash discounts based contractual terms historical trends expectations regarding utilization rates programs estimates allowance doubtful accounts determined based existing contractual payment terms historical payment patterns customers individual customer circumstances analysis days sales outstanding geographic region review local economic environment potential impact government funding reimbursement practices historically amounts uncollectible accounts receivable written insignificant inventories inventories recorded lower cost net realizable value cost determined firstin firstout basis periodically review inventories identify obsolete slowmoving excess otherwise unsaleable items obsolete excess unsaleable items observed alternate uses inventory record inventory valuation reserve charge cost goods sold consolidated statements income establishment inventory valuation reserves together calculation amount reserves requires judgment including consideration many factors estimates future product demand product net selling prices current future market conditions potential product obsolescence among others future commercialization considered probable future economic benefit expected realized based managements judgment capitalize prelaunch inventory costs prior regulatory approval number factors taken consideration including current status regulatory approval process potential impediments approval process safety efficacy anticipated rd initiatives could impact indication compound used viability commercialization marketplace trends december amount prelaunch inventory consolidated balance sheets significant property plant equipment property plant equipment stated cost less accumulated depreciation amortization depreciation amortization recognized using straight line method repairs maintenance costs expensed incurred estimated useful lives years generally follows description estimated useful life buildings improvements shorter years useful life laboratory manufacturing equipment office computer equipment leasehold improvements shorter useful life lease term acquisitions account business combinations using acquisition method accounting requires assets acquired including inprocess research development iprd projects liabilities assumed recorded fair values acquisition date consolidated balance sheets excess purchase price fair value net assets acquired recorded goodwill determination estimated fair value requires us make significant estimates assumptions result may record adjustments fair values assets acquired liabilities assumed within measurement period one year acquisition date corresponding offset goodwill transaction costs associated business combinations expensed incurred determine net assets acquired meet definition business combination acquisition method accounting transaction accounted acquisition assets rather business combination therefore goodwill recorded goodwill intangible assets goodwill represents excess consideration transferred estimated fair value assets acquired liabilities assumed business combination intangible assets indefinite useful lives related purchased iprd projects measured respective fair values acquisition date amortize goodwill intangible assets indefinite useful lives intangible assets related iprd projects considered indefinitelived completion abandonment associated rd efforts development complete generally occurs regulatory approval market product obtained associated assets deemed finitelived amortized based respective estimated useful lives point time test goodwill indefinitelived intangible assets impairment annual basis annual tests become aware events circumstances would indicate fair values assets carrying amounts intangible assets finite useful lives amortized estimated useful lives primarily straightline basis reviewed impairment facts circumstances suggest carrying value assets may recoverable impairment longlived assets longlived assets including property plant equipment finitelived intangible assets reviewed impairment whenever facts circumstances either internally externally may suggest carrying value asset may recoverable indication impairment test recoverability comparing estimated undiscounted future cash flows expected result use asset carrying amount asset asset group excess carrying value asset asset group estimated fair value recognized impairment loss foreign currency translation transaction gains losses hedging contracts nonus entity operations recorded functional currency entity results operations nonus dollar functional currency entities translated us dollars using average currency rates assets liabilities translated using currency rates period end foreign currency translation adjustments recorded component aoci within stockholders equity foreign currency transaction gains losses recorded income expense net consolidated statements income net foreign currency transaction gains losses immaterial years ended december hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions seek limit risk counterparties contracts may unable perform also seek limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrealized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes fair value financial instruments apply fair value accounting financial assets liabilities nonfinancial assets liabilities recognized disclosed fair value financial statements recurring basis define fair value price would received selling asset paid transfer liability orderly transaction market participants measurement date determining fair value measurements assets liabilities required recorded fair value consider principal advantageous market would transact marketbased risk measurements assumptions market participants would use pricing asset liability risks inherent valuation techniques transfer restrictions credit risks derivative financial instruments recognize derivative instruments either assets liabilities fair value consolidated balance sheets changes fair value derivatives recorded period current earnings aoci depending whether derivative designated part hedge transaction type hedge transaction assess inception ongoing basis whether derivatives used hedging transactions effective offsetting changes cash flows fair values hedged items determine forecasted transaction probable occurring discontinue hedge accounting affected portion hedge instrument related unrealized gain loss contract recognized income expense net consolidated statements income income taxes income tax provision computed liability method deferred tax assets liabilities determined based difference financial statement tax basis assets liabilities using enacted tax rates effect year differences expected reverse significant estimates required determining provision income taxes estimates based interpretations applicable tax laws regulations record liabilities related unrecognized tax benefits accordance guidance clarifies accounting uncertainty income taxes recognized enterprises financial statements prescribing minimum recognition threshold measurement attribute financial statement recognition measurement tax position taken expected taken tax return adverse resolution one uncertain tax positions period could material impact results operations period elected account tax global intangible lowtaxed income enacted part tax cuts jobs act tax reform component tax expense period tax incurred recently adopted accounting pronouncements may financial accounting standards board fasb issued topic entities adopting topic option using either full retrospective modified retrospective approach january adopted topic using modified retrospective method applied contracts completed january results reporting periods beginning january presented topic prior period amounts adjusted continue reported accordance historical accounting topic discussed product sales recognized control product transfers generally upon shipment delivery customer certain cases upon corresponding sale customer third party certain product sales deferred sellthrough cash basis methods accounting fees fixed determinable prior adoption topic recognized upon transfer control royalty revenue recognized period corresponding sales corporate partners occur prior adoption topic royalty revenue generally recognized quarter following quarter corresponding sales corporate partners occurred cumulative effect changes made consolidated balance sheets january adoption topic follows millions adjustments due topic december january prepaid current assets longterm assets accrued liabilities longterm obligations retained earnings impact consolidated financial statements result applying topic place topic material january fasb issued accounting standards update financial instruments overall recognition measurement financial assets financial liabilities asu asu changes accounting equity investments financial liabilities fair value option presentation disclosure requirements financial instruments additionally asu clarifies guidance related valuation allowance assessment recognizing deferred tax assets resulting unrealized losses availableforsale debt securities january adopted standard using modified retrospective approach standard requires equity investments readily determinable fair values measured fair value changes fair value recognized earnings result adoption reclassified million unrealized net gain aoci retained earnings january primarily consisted million unrealized gain equity investment galapagos nv august fasb issued accounting standards update derivatives hedging targeted improvements accounting hedging activities asu amendments asu closely align results hedge accounting risk management activities asu also amends presentation disclosure requirements eases documentation effectiveness assessment requirements january early adopted standard prospective basis upon adoption asu longer recognize hedge ineffectiveness consolidated statements income instead recognize entire change fair value hedge contract aoci adoption material impact consolidated financial statements primary impact adoption required disclosure changes see note derivative financial instruments additional information march fasb issued accounting standards update income taxes topic amendments sec paragraphs pursuant sec staff accounting bulletin asu asu amends topic incorporating sec staff accounting bulletin sab issued december sab provides guidance accounting effects tax reform allows company record provisional amounts measurement period extend beyond one year enactment date see note income taxes additional information recently issued accounting pronouncements yet adopted february fasb issued accounting standards update leases topic topic amends number aspects lease accounting including requiring lessees recognize leases term greater one year rightofuse asset corresponding liability measured present value lease payments july fasb issued supplemental adoption guidance clarification topic within asu codification improvements topic leases asu leases topic targeted improvements guidance become effective us beginning first quarter modified retrospective transition approach required plan adopt standards effective date recording cumulative effect adjustment opening balance retained earnings january based lease portfolio december anticipate recognition lease assets liabilities approximately million consolidated balance sheet upon adoption material impact consolidated statements income elect practical expedients upon transition reassess prior conclusions related contracts containing leases lease classification initial direct costs also elect practical expedient lessees combine lease nonlease components asset classes process finalizing key system functionality updating controls procedures maintaining accounting lease portfolio new guidance june fasb issued accounting standards update financial instrumentscredit losses measurement credit losses financial instruments asu asu requires measurement recognition expected credit losses financial assets guidance become effective us beginning first quarter must adopted using modified retrospective approach certain exceptions early adoption permitted beginning first quarter evaluating impact adoption standard consolidated financial statements november fasb issued accounting standards update collaborative arrangements topic clarifying interaction topic topic asu asu clarifies certain transactions collaborative arrangement participants accounted revenue topic collaborative arrangement participant customer context unit account adds unitofaccount guidance topic align guidance topic precludes entities presenting amounts related transactions collaborative arrangement participant customer revenue unless transactions directly related thirdparty sales guidance become effective us beginning first quarter applied retrospectively january initially adopted topic early adoption permitted evaluating impact adoption standard currently expect material impact revenue revenues disaggregation revenues following table disaggregates product sales product geographic region disaggregates royalty contract revenues geographic region years ended december information years ended december adjusted accordance modified retrospective adoption topic continues reported accordance historical accounting topic year ended december year ended december year ended december millions us europe international total us europe international total us europe international total product sales atripla biktarvy compleraeviplera descovy genvoya odefsey stribild truvada hiv revenue share symtuza ambisome epclusa harvoni letairis ranexa vemlidy viread vosevi yescarta zydelig total product sales royalty contract revenues total revenues notes includes emtriva tybost represents gileads revenue cobicistat c emtricitabine ftc tenofovir alafenamide taf symtuza darunavircftctaf fixed dose combination product commercialized janssen sciences ireland uc janssen includes cayston hepsera sovaldi revenues recognized performance obligations satisfied prior periods year ended december revenues recognized performance obligations satisfied prior years related royalties licenses intellectual property million changes estimates variable consideration related sales made prior years resulted million decrease revenues year ended december contract balances contract assets consist unbilled amounts primarily arrangements licensing intellectual property predominant performance obligation totaled million million december january respectively contract liabilities material december january fair value measurements determine fair value financial nonfinancial assets liabilities using fair value hierarchy establishes three levels inputs may used measure fair value follows level inputs include quoted prices active markets identical assets liabilities level inputs include observable inputs level inputs quoted prices similar assets liabilities quoted prices identical similar assets liabilities markets active inputs observable corroborated observable market data substantially full term asset liability marketable securities review trading activity pricing measurement date sufficient quoted pricing identical securities available use market pricing observable market inputs similar securities obtained various thirdparty data providers inputs either represent quoted prices similar assets active markets derived observable market data level inputs include unobservable inputs supported little market activity significant fair value underlying asset liability level assets liabilities include whose fair value measurements determined using pricing models discounted cash flow methodologies similar valuation techniques significant management judgment estimation financial instruments consist primarily cash cash equivalents marketable debt securities accounts receivable foreign currency exchange contracts equity securities accounts payable shortterm longterm debt cash cash equivalents marketable debt equity securities foreign currency exchange contracts reported respective fair values consolidated balance sheets shortterm longterm debt reported amortized costs consolidated balance sheets remaining financial instruments reported consolidated balance sheets amounts approximate current fair values following table summarizes types assets liabilities measured fair value recurring basis level within fair value hierarchy millions december december level level level total level level level total assets availableforsale debt securities us treasury securities certificates deposit us government agencies securities nonus government securities corporate debt securities residential mortgage assetbacked securities marketable equity securities money market funds equity securities deferred compensation plan foreign currency derivative contracts total liabilities deferred compensation plan foreign currency derivative contracts total year ended december changes fair value marketable equity securities resulted net unrealized gains million included income expense net consolidated statements income following table summarizes classification marketable equity securities consolidated balance sheets millions december december cash cash equivalents prepaid current assets longterm assets total availableforsale debt securities classified cash equivalents shortterm marketable securities longterm marketable securities consolidated balance sheets see note availableforsale debt securities additional information level inputs estimate fair values level instruments taking consideration valuations obtained thirdparty pricing services pricing services utilize industry standard valuation models including incomebased marketbased approaches significant inputs observable either directly indirectly estimate fair value inputs include reported trades brokerdealer quotes similar securities issuer credit spreads benchmark securities prepaymentdefault projections based historical data observable inputs substantially foreign currency derivative contracts maturities within month time horizon counterparties minimum credit rating equivalent sp global ratings moodys investors service inc fitch ratings inc estimate fair values contracts taking consideration valuations obtained thirdparty valuation service utilizes incomebased industry standard valuation model significant inputs observable either directly indirectly inputs include foreign currency exchange rates london interbank offered rates libor swap rates inputs applicable observable commonly quoted intervals total estimated fair values shortterm longterm debt determined using level inputs based quoted market values approximately billion billion december respectively carrying values billion billion december respectively level inputs december assets liabilities measured using level inputs recurring basis contingent consideration liabilities immaterial nonrecurring basis measure certain assets including intangible assets fair value carrying value asset exceeds fair value recorded impairment charge million write zero carrying value kite program antibcma evaluated treatment multiple myeloma see note intangible assets additional information policy recognize transfers level classification actual date event change circumstances caused transfer transfers level level level periods presented availableforsale debt securities following table summarizes availableforsale debt securities millions december december gross gross gross gross amortized unrealized unrealized estimated amortized unrealized unrealized estimated cost gains losses fair value cost gains losses fair value us treasury securities certificates deposit us government agencies securities nonus government securities corporate debt securities residential mortgage assetbacked securities total following table summarizes classification availableforsale debt securities consolidated balance sheets millions december december cash cash equivalents shortterm marketable securities longterm marketable securities total following table summarizes availableforsale debt securities contractual maturity millions december amortized cost fair value within one year one year five years five years ten years ten years total following table summarizes availableforsale debt securities continuous unrealized loss position deemed otherthan temporarily impaired millions less months months greater total gross gross gross unrealized estimated unrealized estimated unrealized estimated losses fair value losses fair value losses fair value december us treasury securities us government agencies securities nonus government securities corporate debt securities residential mortgage assetbacked securities total december us treasury securities us government agencies securities nonus government securities corporate debt securities residential mortgage assetbacked securities total held total positions unrealized loss position december respectively based review securities believe otherthantemporary impairments december intend sell securities believe required sell securities recovery amortized cost basis gross realized gains gross realized losses material years presented derivative financial instruments operations foreign countries expose us market risk associated foreign currency exchange rate fluctuations us dollar various foreign currencies primarily euro order manage risk may hedge portion foreign currency exposures related outstanding monetary assets liabilities well forecasted product sales using foreign currency exchange forward option contracts general market risk related contracts offset corresponding gains losses hedged transactions credit risk associated contracts driven changes interest currency exchange rates result varies time working major banks closely monitoring current market conditions seek limit risk counterparties contracts may unable perform also seek limit risk loss entering contracts permit net settlement maturity therefore overall risk loss event counterparty default limited amount unrecognized gains outstanding contracts ie contracts positive fair value date default enter derivative contracts trading purposes hedge exposure foreign currency exchange rate fluctuations certain monetary assets liabilities entities denominated non functional currency derivative instruments use hedge exposure designated hedges result changes fair value recorded income expense net consolidated statements income hedge exposure foreign currency exchange rate fluctuations forecasted product sales denominated nonfunctional currency derivative instruments use hedge exposure designated cash flow hedges maturities months less upon executing hedging contract quarterly thereafter assess hedge effectiveness using regression analysis prior january excluded time value effectiveness testing recognized changes time value hedge income expense net consolidated statements income starting january include time value effectiveness testing entire change value hedge contracts recorded unrealized gains losses aoci within stockholders equity consolidated balance sheets unrealized gains losses aoci reclassified product sales respective hedged transactions affect earnings majority gains losses related hedged forecasted transactions reported aoci december expected reclassified product sales within months cash flow effects derivative contracts years ended december included within net cash provided operating activities consolidated statements cash flows notional amounts foreign currency exchange contracts outstanding billion billion december respectively derivative contracts allow us right offset assets liabilities presented amounts gross basis following table summarizes classification fair values derivative instruments consolidated balance sheets millions december asset derivatives liability derivatives fair classification fair value classification value derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities total derivatives designated hedges total derivatives december asset derivatives liability derivatives fair classification fair value classification value derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities foreign currency exchange contracts longterm assets longterm obligations total derivatives designated hedges derivatives designated hedges foreign currency exchange contracts current assets accrued liabilities total derivatives designated hedges total derivatives following table summarizes effect foreign currency exchange contracts consolidated financial statements millions year ended december derivatives designated hedges gains losses recognized aoci gains losses reclassified aoci product sales gains losses recognized income expense net derivatives designated hedges gains losses recognized income expense net time time may discontinue cash flow hedges result record related amounts income expense net consolidated statements income material amounts recorded income expense net consolidated statements income years presented result discontinuance cash flow hedges december held foreign currency exchange contracts following table summarizes potential effect offsetting derivatives type financial instrument consolidated balance sheets millions december offsetting derivative assetsliabilities gross amounts offset consolidated balance sheets gross amounts offset amounts assetsliabilities gross amounts consolidated balance presented consolidated derivative financial cash collateral net amount description recognized assetsliabilities sheets balance sheets instruments receivedpledged legal offset derivative assets derivative liabilities december offsetting derivative assetsliabilities gross amounts offset consolidated balance sheets gross amounts offset amounts assetsliabilities gross amounts consolidated balance presented consolidated derivative financial cash collateral net amount description recognized assetsliabilities sheets balance sheets instruments receivedpledged legal offset derivative assets derivative liabilities acquisitions kite pharma inc october acquisition date completed tender offer outstanding common stock kite pharma inc kite per share cash result kite became whollyowned subsidiary acquisition kite helps establish foundation improving treatment hematological malignancies solid tumors consideration transferred acquisition million consisting million cash outstanding kite common stockholders million cash payment vested equity award holders million warrant holders million representing portion replaced stockbased awards attributable precombination period addition million excluded consideration transferred representing portion replaced stock based awards attributable post combination period expected recognized acquisition kite accounted business combination using acquisition method accounting method requires among things assets acquired liabilities assumed recognized fair value acquisition date determination estimated fair value requires us make significant estimates assumptions recorded million reduction goodwill primarily due revision deferred income taxes result finalization kites preacquisition federal income tax return fair value estimates assets acquired liabilities assumed completed following table summarizes acquisition date fair values assets acquired liabilities assumed consideration transferred millions cash cash equivalents identifiable intangible assets indefinitelived intangible assets iprd outlicense acquired deferred income taxes assets acquired liabilities assumed net total identifiable net assets goodwill total consideration transferred identifiable intangible assets acquired intangible assets primarily related iprd axicabtagene ciloleucel kite ktex formerly ktec evaluated treatment adult pediatric acute lymphoblastic leukemia estimated aggregate fair value million acquisition date intangible assets related iprd projects considered indefinitelived assets completion abandonment associated rd efforts october upon fda approval yescarta treatment adult patients relapsed refractory dlbcl two lines systemic therapy million purchased iprd reclassified finitelived intangible asset amortized estimated useful life years using straight line method recorded impairment charge million write zero estimated fair value kite program see note intangible assets additional information additionally acquired outlicensing arrangement daiichi sankyo company limited estimated fair value million acquisition date definitelived intangible asset amortized estimated useful life years straightline basis fair value determined estimating probabilityweighted net cash flows attributable outlicense discounted present value using discount rate represents estimated rate market participants would use value intangible asset goodwill million goodwill represents excess consideration transferred fair values assets acquired liabilities assumed represents future economic benefits arising assets acquired could individually identified separately recognized none goodwill deductible income tax purposes cell design labs inc december acquired issued outstanding stock cell design labs inc privately held company cell design labs addition approximately shares cell design labs obtained acquisition kite acquisition gained new technology platforms enhance research development efforts cellular therapy cash consideration totaled million net acquired cash additionally shareholders cell design labs us eligible receive contingent development regulatory milestonebased payments million equity interest cell design labs carrying value million transaction accounted asset acquisition result million expensed acquired iprd within research development expenses consolidated statements income nimbus apollo inc may acquired nimbus apollo inc privately held company acetylcoa carboxylase inhibitor program evaluated potential treatment nonalcoholic steatohepatitis hepatocellular carcinoma diseases consideration included payment million contingent development regulatory milestonebased payments million transaction accounted asset acquisition result payment million expensed acquired iprd within research development expenses consolidated statements income based achievement certain clinical development milestones recorded million expense within research development expenses consolidated statements income inventories inventories summarized follows millions december raw materials work process finished goods total reported inventories longterm assets total amounts reported longterm assets primarily consisted raw materials december year ended december recorded inventory reserves million million related excess raw materials primarily due sustained decrease demand harvoni inventory reserves recorded years ended december material property plant equipment property plant equipment summarized follows millions december land land improvements buildings improvements including leasehold improvements laboratory manufacturing equipment office computer equipment construction progress subtotal less accumulated depreciation amortization total office computer equipment includes capitalized software unamortized capitalized software costs consolidated balance sheets million million december respectively capitalized interest construction inprogress included property plant equipment interest capitalized material intangible assets following table summarizes intangible assets net millions december december gross foreign currency gross carrying accumulated translation net carrying carrying accumulated net carrying amount amortization adjustment amount amount amortization amount finitelived assets intangible asset sofosbuvir intangible asset axicabtagene ciloleucel dlbcl intangible asset ranexa total finitelived assets indefinitelived assets iprd total intangible assets amortization expense related finitelived intangible assets included cost goods sold consolidated statements income totaled billion million million years ended december respectively entered agreement japan tobacco inc japan tobacco acquire rights market distribute certain products hiv portfolio japan connection agreement recorded intangible asset million reflecting estimated fair value marketingrelated rights acquired japan tobacco intangible asset amortized nine years beginning january amortization expense classified selling expense recorded selling general administrative expenses consolidated statements income see note collaborative arrangements additional information concluded kite program justify efforts based totality clinical data gathered discontinued program result carrying value iprd relating kite program written zero recorded impairment charge million within research development expenses consolidated statements income iprd impairment charges recorded million iprd impairment charges recorded within research development expenses consolidated statements income entered collaboration agreement gadeta bv gadeta develop gamma delta cell receptor therapies various cancers gadeta vie consolidate upon consolidation recognized million indefinitelived intangible asset relating iprd see note collaborative arrangements additional information december estimated future amortization expense associated finitelived intangible assets follows millions fiscal year amount thereafter total financial information accrued liabilities components accrued liabilities summarized follows millions december compensation employee benefits accrued payment marketingrelated rights acquired japan tobacco income taxes payable accrued expenses total collaborative arrangements enter collaborative arrangements third parties development commercialization certain products product candidates arrangements involve two parties active participants operating activities collaboration exposed significant risks rewards depending commercial success activities arrangements may include nonrefundable upfront payments payments us options acquire certain rights contingent obligations us potential development regulatory milestone payments andor salesbased milestone payments royalty payments revenue profitsharing arrangements costsharing arrangements equity investments combination terms janssen compleraeviplera odefsey entered license collaboration agreement janssen sciences ireland uc janssen formerly tibotec pharmaceuticals develop commercialize fixeddose combination truvada janssens nonnucleoside reverse transcriptase inhibitor rilpivirine combination approved united states european union sold brand name complera united states eviplera european union agreement amended expand collaboration include another product containing janssens rilpivirine emtricitabine tenofovir alafenamide odefsey amended agreement janssen granted us exclusive license compleraeviplera odefsey worldwide retained rights distribute combination products certain countries outside united states neither party restricted combining drugs drug products except similar components compleraeviplera odefsey responsible manufacturing compleraeviplera odefsey lead role registration distribution commercialization products except countries janssen distributes janssen exercised right codetail combination product countries selling party financial provisions amendment selling party sets price combined products parties share revenues based ratio net selling prices partys components subject certain restrictions adjustments retain specified percentage janssens share revenues major markets sales products included product sales janssens shares revenues included cost goods sold consolidated statements income cost goods sold relating janssens shares million million million years ended december respectively termination agreement may product country basis depend circumstances including withdrawal product market material breach either party expiry revenue share payment term may terminate agreement without cause respect countries sell products case janssen right become selling party country product launched market fewer years symtuza amended license collaboration agreement janssen develop commercialize fixeddose combination janssens darunavir cobicistat emtricitabine tenofovir alafenamide combination approved united states european union july september respectively sold brand name symtuza terms amendment granted janssen exclusive license symtuza worldwide janssen responsible manufacturing registration distribution commercialization symtuza worldwide responsible intellectual property related cobicistat emtricitabine tenofovir alafenamide gilead compounds exclusive supplier gilead compounds neither party restricted combining drugs drug products except similar components symtuza janssen sets price symtuza parties share revenue based ratio net selling prices partys components subject certain restrictions adjustments intellectual property license supply obligations related gilead compounds accounted single performance obligation license deemed predominant item revenue share relates recognize share symtuza revenue period corresponding sales symtuza janssen occur record share symtuza revenue product sales consolidated statements income primarily supply gilead compounds janssen symtuza see note revenues revenue recognized periods presented termination agreement may product country basis depend circumstances including withdrawal product market material breach either party expiry revenue share payment term janssen may terminate agreement without cause countrybycountry basis case gilead right become selling party countryies product launched market fewer years janssen may also terminate entire agreement without cause japan tobacco japan tobacco granted us exclusive rights develop commercialize elvitegravir novel hiv integrase inhibitor countries world excluding japan japan tobacco retained rights paid royalty us based product sales japan agreement responsible seeking regulatory approval territories required use diligent efforts commercialize elvitegravir treatment hiv infection bear costs expenses associated commercialization efforts pay royalty japan tobacco based product sales japan tobacco also marketed distributed certain products hiv portfolio japan paid royalty us based product sales received approval stribild genvoya elvitegravircontaining products respectively sales products included product sales royalties due japan tobacco based product sales included cost goods sold royalties due japan tobacco based product sales japan included royalty contract revenues consolidated statements income royalty expenses recognized million million million years ended december respectively royalty income recognized material periods presented effective december entered agreement japan tobacco acquire rights market distribute certain products hiv portfolio japan expand rights develop commercialize elvitegravir include japan responsible marketing products january terms agreement obligated pay japan tobacco million cash million paid upfront payment remaining million reflected accrued liabilities consolidated balance sheets december recognized intangible asset million reflecting estimated fair value marketingrelated rights acquired japan tobacco remaining million recorded prepaid current assets consolidated balance sheets intangible asset amortized nine years representing period majority benefits expected derived applicable products hiv portfolio amortization expense classified selling expense recorded selling general administrative expenses consolidated statements income termination agreement may product country basis depend circumstances including material breach either party expiry royalty payment term may also terminate entire agreement without cause galapagos closed license collaboration agreement galapagos nv galapagos clinicalstage biotechnology company based belgium development commercialization filgotinib jakselective inhibitor evaluated inflammatory disease indications upon closing license collaboration agreement made upfront license fee payment million million equity investment galapagos subscribing new shares price per share including issuance premium result received million new shares galapagos representing outstanding share capital closing license collaboration agreement license fee payment million issuance premium equity investment million recorded within research development expenses consolidated statements income equity investment net issuance premium recorded prepaid current assets consolidated balance sheets december fair value investment million galapagos eligible receive us development regulatory milestonebased payments million salesbased milestone payments million plus tiered royalties global net sales ranging exception certain copromotion territories profits would shared equally years ended december milestone payments made galapagos material year ended december recorded million expense based achievement certain clinical development milestones within research development expenses consolidated statements income terms agreement exclusive worldwide royaltybearing sublicensable license filgotinib products containing filgotinib primarily responsible development seeking regulatory approval related filgotinib responsible galapagos responsible development costs incurred years presented payments galapagos us development costs material also responsible manufacturing commercialization activities galapagos exercised option copromote filgotinib uk germany france italy spain netherlands belgium luxembourg territories galapagos share profits equally termination agreement may country basis depend circumstances including expiration royalty term copromotion territory sale generic product material breach either party may also terminate entire agreement without cause following certain period gadeta july entered collaboration arrangement gadeta privatelyheld company based utrecht netherlands develop gamma delta cell receptor therapies various cancers financial terms provide rd funding collaboration gadeta eligible receive future payments upon achievement certain regulatory milestones addition made upfront purchase equity gadeta gadetas shareholders may acquire additional equity gadeta upon achievement certain rd milestones also exclusive option acquire remaining equity gadeta million adjusted closing cash transaction expenses closing indebtedness option exercisable discretion gadeta vie primary beneficiary power direct activities gadeta significantly impact economic performance result financial terms described upon initial consolidation gadeta recorded assets million primarily intangible assets related iprd million noncontrolling interest consolidated balance sheets gadeta meet definition business defined asc business combinations result goodwill recognized bristolmyers squibb company north america entered collaboration arrangement bristolmyers squibb company bms develop commercialize single tablet regimen containing truvada bmss sustiva efavirenz united states canada combination approved use united states sold brand name atripla bms structured collaboration joint venture operated limited liability company consolidated december terminated bmss participation collaboration following launch generic version sustiva us became sole owner joint venture bms permitted commercialize atripla united states canada entitled receive us certain fees based net sales atripla declining annual scale may continue purchase efavirenz bms cost plus markup needed continue manufacturing atripla united states canada markets year ended december recorded million fee expenses within cost goods sold consolidated statements income europe gilead sciences ireland uc whollyowned subsidiary bms entered collaboration agreement sets forth terms conditions bms commercialize distribute atripla european union iceland liechtenstein norway switzerland collectively european territory parties formed limited liability company consolidate manufacture atripla distribution european territory using efavirenz purchases bms bmss estimated net selling price efavirenz european territory responsible manufacturing product distribution inventory management warehousing local subsidiaries primary responsibility order fulfillment collection receivables customer relations handling sales returns territories bms promote atripla general parties share revenues outofpocket expenses proportion net selling prices components atripla truvada efavirenz starting except limited number activities jointly managed parties longer coordinate detailing promotional activities european territory responsible accounting financial reporting tax reporting collaboration december efavirenz purchased bms bmss estimated net selling price efavirenz european territory included inventories consolidated balance sheets parties also formed limited liability company hold marketing authorization atripla european territory primary responsibility regulatory activities major market countries parties agreed independently continue use commercially reasonable efforts promote atripla agreement terminate upon expiration lasttoexpire patent affords market exclusivity atripla one components european territory addition since december either party may terminate agreement reason termination effective two calendar quarters notice termination nonterminating party right continue sell atripla become continuing party obligated pay terminating party certain fees based net sales threeyear period following effective date termination event continuing party decides sell atripla effective date termination date atripla withdrawn country date third party assumes distribution atripla whichever earlier collaboration arrangements individually significant entered several collaboration arrangements resulted cash payments million million recorded front collaboration expense within research development expenses consolidated statements income remaining amounts recorded current longterm assets consolidated balance sheets consider collaborations arrangements individually material made material initial cash payments related individually insignificant collaboration arrangements financial terms arrangements may required make payments upon achievement various developmental regulatory commercial milestones could significant addition may required pay significant royalties future sales products related arrangements commercialized payment amounts however contingent upon occurrence various future events high degree uncertainty occurrence future milestone payments royalties reflected consolidated statements income corresponding events become probable debt credit facilities following table summarizes carrying amount borrowings various financing arrangements millions december type borrowing issue date due date interest rate senior unsecured september september senior unsecured september september month libor term loan october october variable senior unsecured september march month libor senior unsecured march april senior unsecured september september senior unsecured september september month libor senior unsecured november february senior unsecured september september term loan october october variable senior unsecured march april senior unsecured december december senior unsecured september march senior unsecured september september term loan october october variable senior unsecured september september senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march senior unsecured september september senior unsecured september september senior unsecured december december senior unsecured march april senior unsecured november february senior unsecured september march senior unsecured september march total debt net less current portion total longterm debt net senior unsecured notes connection acquisition kite issued billion aggregate principal amount senior unsecured notes registered offering consisting million principal amount floating rate notes due september million principal amount floating rate notes due march million principal amount floating rate notes due september collectively floating rate notes billion principal amount senior notes due september fixed rate notes collectively floating rate notes notes terms summarized table repaid maturity million principal balance related floating rate notes collectively refer notes senior unsecured notes issued september notes september notes march november notes march december notes senior notes repaid maturity billion principal balance related notes senior notes except floating rate notes may redeemed option redemption price equal greater principal amount notes redeemed ii sum determined independent investment banker present values remaining scheduled payments principal interest notes redeemed exclusive interest accrued date redemption discounted redemption date semiannual basis treasury rate plus makewhole premium defined indenture senior notes maturing also call feature exercisable option redeem notes par whole part one six months immediately preceding maturity case accrued unpaid interest also required redeemed date redemption option redeem series floating rate notes whole part prior maturity date event occurrence change control downgrade rating senior notes investment grade moodys investors service inc sp global ratings holders may require us purchase portion notes price equal aggregate principal amount notes repurchased plus accrued unpaid interest date repurchase required comply certain covenants senior notes december violation covenants interest expense senior notes related contractual coupon rates amortization debt discount issuance costs billion billion million respectively term loan facilities september entered billion aggregate principal amount term loan facility credit agreement consisting billion principal amount day senior unsecured term loan facility billion principal amount threeyear senior unsecured term loan facility billion principal amount fiveyear senior unsecured term loan facility collectively term loan facilities october drew billion principal amount term loan facilities used proceeds finance acquisition kite billion repaid remaining billion repaid term loan facility credit agreement terminated credit facilities entered billion fiveyear revolving credit facility agreement maturing may fiveyear revolving credit agreement revolving credit facility used working capital requirements general corporate purposes including without limitation acquisitions december amounts outstanding fiveyear revolving credit agreement fiveyear revolving credit agreement contains customary representations warranties affirmative negative covenants events default december violation covenants loans fiveyear revolving credit agreement bear interest either eurodollar rate plus applicable percentage ii base rate plus applicable percentage defined fiveyear revolving credit agreement may terminate reduce commitments may prepay loans fiveyear revolving credit agreement whole part time without premium penalty contractual maturities financing obligations december aggregate future principal maturities financing obligations next five years based contractual due dates follows millions contractual maturities commitments contingencies lease arrangements lease facilities equipment related primarily administrative rd sales marketing activities various longterm noncancelable operating leases united states international markets leases expire various dates many leases containing options renew lease expense operating leases million million million respectively aggregate undiscounted noncancelable future minimum rental payments operating leases follows millions thereafter total legal proceedings party various legal actions significant described recognize accruals actions extent conclude loss probable reasonably estimable accrue best estimate loss within range however estimate range better accrue minimum amount range determine loss reasonably possible loss range loss estimated disclose possible loss unless otherwise noted possible determine outcome matters reasonably estimate maximum potential exposure range possible loss recognize accruals actions described consolidated balance sheets december believe losses probable litigation related sofosbuvir january acquired pharmasset inc pharmasset acquisition acquired sofosbuvir nucleotide analog acts inhibit replication hepatitis c virus hcv december received approval us food drug administration fda sofosbuvir known commercially sovaldi sofosbuvir also included marketed hcv products received number claims regarding sofosbuvir carefully considered claims prior following acquisition believe without merit predict ultimate outcome claims range loss aware patents patent applications owned third parties may future alleged parties cover use hcv products third parties obtain valid enforceable patents successfully prove infringement patents hcv products could required pay significant monetary damages predict ultimate outcome intellectual property claims related hcv products spent continue spend significant resources defending claims litigation idenix pharmaceuticals inc idenix universita degli studi di cagliari udsg centre national de la recherche scientifique luniversite montpellier ii idenix udsg centre national de la recherche scientifique luniversit montpellier ii sued us us district court district delaware alleging commercialization sofosbuvir infringe us patent patent also idenix udsg sued us us district court district massachusetts alleging commercialization sofosbuvir infringe us patent nos patent patent court transferred massachusetts litigation us district court district delaware prior trial idenix committed give us covenant sue respect claims arising patent related sofosbuvir withdrew patent trial jury trial held patent jury found willfully infringed asserted claims patent awarded idenix billion past damages judge invalidated idenixs patent vacated jurys award billion past damages idenix appealed decision us court appeals federal circuit cafc briefing complete believe delaware courts decision correctly found matter law patent invalid remain confident merits case appeal believe possibility material adverse outcome matter remote european patent office epo granted idenix 's european patent patent corresponds patent day patent granted filed opposition epo seeking revoke patent opposition hearing held epo ruled favor revoked patent idenix appealed idenix also initiated infringement proceedings us germany france alleging commercialization sovaldi would infringe german french counterparts patent german court dsseldorf determined idenix patent highly likely invalid stayed infringement proceedings pending outcome opposition hearing held epo idenix appealed decision german court staying proceedings upon idenixs request french proceedings stayed litigation merck co inc merck merck contacted us requesting pay royalties sales sofosbuvir obtain license us patent patent us patent patent coowns ionis pharmaceuticals inc patents cover compounds include may relate sofosbuvir filed lawsuit us district court northern district california seeking declaratory judgment merck patents invalid infringed initially jury determined established mercks patents invalid awarded merck million damages however court ruled favor defense unclean hands determined merck may recover damages us patents cafc affirmed courts decision unclean hands us supreme court denied mercks petition review merits portion case final litigation university minnesota university minnesota university obtained patent patent purports broadly cover nucleosides antiviral anticancer activity university filed lawsuit us us district court district minnesota alleging commercialization sofosbuvircontaining products infringes patent believe patent invalid infringed continued commercialization sofosbuvir court granted motion transfer case california also filed four petitions inter partes review uspto patent trial appeal board ptab alleging asserted claims invalid anticipation obviousness district court stayed litigation ptab rules petitions inter partes review litigation related axicabtagene ciloleucel acquired kite whollyowned subsidiary acquisition acquired axicabtagene ciloleucel chimeric antigen receptor car cell therapy received approval fda axicabtagene ciloleucel known commercially yescarta patents patent applications claim axicabtagene ciloleucel chimeric dna segments third parties may may obtain rights patents allegedly could used prevent attempt prevent us commercializing axicabtagene ciloleucel require us obtain license order commercialize axicabtagene ciloleucel example aware juno therapeutics inc juno exclusively licensed patent patent issued sloan kettering cancer center september juno sloan kettering cancer center filed lawsuit kite us district court central district california alleging commercialization axicabtagene ciloleucel infringes patent october following fda approval yescarta juno filed second complaint alleging axicabtagene ciloleucel infringes patent juno subsequently moved dismiss september complaint maintained october complaint court set trial date december lawsuit predict ultimate outcome intellectual property claims related axicabtagene ciloleucel junos patent upheld valid juno successfully proves infringement patent axicabtagene ciloleucel could required pay significant monetary damages could prevented selling yescarta unless able obtain license patent license may available commercially reasonable terms litigation related bictegravir viiv healthcare company viiv filed lawsuit us us district court delaware alleging commercialization bictegravir known commercially biktarvy infringes viivs us patent patent issued shionogi co ltd glaxosmithkline llc patent compound patent covering viivs dolutegravir bictegravir structurally different dolutegravir believe bictegravir infringe claims patent extent viivs patent claims interpreted cover bictegravir believe claims invalid us patent trademark office uspto granted us patents covering bictegravir court set trial date september lawsuit viiv also filed lawsuit us federal court canada alleging activities relating bictegravir product infringed viivs canadian patent patent issued shionogi co ltd viiv patent compound patent covering viivs dolutegravir believe bictegravir infringe claims patent extent viivs patent claims interpreted cover bictegravir believe claims invalid predict ultimate outcome intellectual property claims related bictegravir viivs patents upheld valid viiv successfully proves infringement patents bictegravir could required pay significant monetary damages litigation generic manufacturers part approval process products fda granted us new chemical entity nce exclusivity period manufacturers applications approval generic versions product approved generic manufacturers may challenge patents protecting products granted nce exclusivity one year prior end nce exclusivity period generic manufacturers sought may continue seek fda approval similar identical drug abbreviated new drug application anda application form typically used manufacturers seeking approval generic drug sale generic versions products earlier patent expiration would significant negative effect revenues results operations seek approval generic version product nce status generic company may submit anda fda four years branded products approval current legal proceedings significance generic manufacturers include hiv products received notice strides pharma inc strides submitted anda fda requesting permission manufacture market generic version truvada notice strides alleges two patents associated emtricitabine four patents associated emtricitabine tenofovir disoproxil fumarate fixeddose combination invalid unenforceable andor infringed strides manufacture use sale generic version truvada response filed lawsuit strides us district court district new jersey infringement patents reached agreement strides resolve lawsuit dismissed settlement agreement filed federal trade commission department justice required law received notice zydus pharmaceuticals usa inc zydus submitted anda fda requesting permission manufacture market generic versions truvada various dosage strengths notice zydus alleges two patents associated emtricitabine four patents associated emtricitabine tenofovir disoproxil fumarate fixeddose combination invalid unenforceable andor infringed zydus manufacture use sale generic versions truvada various dosage strengths response filed lawsuit zydus us district court district new jersey infringement patents received notice mylan pharmaceuticals inc mylan submitted anda fda requesting permission manufacture market generic version stribild notice mylan alleges one patent owned japan tobacco inc jt associated elvitegravir invalid unenforceable andor infringed mylans manufacture use sale generic version stribild jt filed lawsuit mylan us district court northern district west virginia infringement patent hcv products received notices natco pharma limited natco teva pharmaceuticals teva submitted anda fda requesting permission manufacture market generic version sovaldi tevas notice alleges nine patents associated sofosbuvir invalid unenforceable andor infringed tevas manufacture use sale generic versions sovaldi response filed lawsuits teva us district court district new jersey us district court district delaware infringement patents natcos notice alleges two patents associated sofosbuvir invalid unenforceable andor infringed natcos manufacture use sale generic versions sovaldi natco challenge patents listed orange book sovaldi also filed lawsuits natco us district court district new jersey us district court district delaware infringement patents reached agreement teva resolve lawsuit dismissed settlement agreement filed federal trade commission department justice required law european patent claims several parties filed oppositions epo requesting revocation one granted european patents covering sofosbuvir expires epo upheld validity certain claims sofosbuvir patent appealed decision seeking restore original claims several original opposing parties also appealed requesting full revocation appeal process may take several years several parties filed oppositions epo requesting revocation granted european patent relating sofosbuvir expires epo conducted oral hearing opposition upheld claims two original opposing parties appealed requesting full revocation appeal process may take several years several parties filed oppositions epo requesting revocation granted european patent covering taf expires epo upheld validity claims taf patent three parties appealed decision appeal process may take several years several parties filed oppositions epo requesting revocation granted european patent relating taf hemifumarate expires responded oppositions hearing held february patent upheld hearing opposing parties may choose appeal decision could take several years conclude three parties filed oppositions epo requesting revocation granted european patent covering cobicistat expires epo upheld validity claims cobicistat patent one original opposing parties appealed decision appeal process may take several years confident strength patents predict ultimate outcome oppositions unsuccessful defending oppositions patent claims may narrowed revoked patent protection sofosbuvir taf cobicistat european union could substantially shortened eliminated entirely patents revoked european patents granted covering compounds exclusivity may based entirely regulatory exclusivity granted european medicines agency sovaldi granted regulatory exclusivity prevent generic sofosbuvir entering european union years following approval sovaldi january lose patent protection sofosbuvir prior revenues results operations could negatively impacted years including succeeding year exclusivity lost may cause stock price decline government investigations related litigation received subpoena us attorneys office northern district california requesting documents related manufacture related quality distribution practices complera atripla truvada viread emtriva hepsera letairis cooperated governments inquiry us department justice informed us following investigation declined intervene false claims act lawsuit filed two former employees also former employees served first amended complaint us district court northern district california issued order granting entirety without prejudice motion dismiss first amended complaint plaintiffs filed second amended complaint district court issued order granting motion dismiss second amended complaint plaintiffs filed notice appeal us court appeals ninth circuit ninth circuit granted motion stay case pending appeal us supreme court filed petition writ certiorari us supreme court solicitor general submitted brief united states supreme court stating intention file motion dismiss federal false claims act january supreme court denied petition case remanded district court received subpoena us attorneys office district massachusetts requesting documents related support c organizations provide financial assistance patients documents concerning provision financial assistance patients hcv products cooperating inquiry received subpoena us attorneys office district massachusetts requesting documents related copay coupon program medicaid price reporting methodology cooperating inquiry received voluntary request information us attorneys office eastern district pennsylvania requesting information related reimbursement support offerings clinical education programs interactions specialty pharmacies sovaldi harvoni received another voluntary request information related speaker programs advisory boards hcv hepatitis b virus hbv products cooperating voluntary requests received subpoena california department insurance alameda county district attorneys office requesting documents related marketing activities reimbursement support offerings clinical education programs interactions specialty pharmacies harvoni sovaldi cooperating inquiry received subpoena us department health human services requesting documents related frontlines communities united states focus program cooperated inquiry february government informed us declined intervene false claims act qui tam lawsuit related inquiry also received subpoena us attorneys office southern district new york requesting documents related promotional speaker programs hiv cooperating inquiry products liability plaintiffs filed purported mass action us us district court northern district california holley action plaintiffs alleged suffered kidney andor bone injuries result using viread truvada atripla complera andor stribild alleged altered design medications replacing one active ingredients tenofovir disoproxil fumarate tdf allegedly superior ingredient tenofovir alafenamide fumarate andor reducing dose tdf stribild failed adequately warn plaintiffs physicians kidney bone risks viread truvada atripla complera stribild need monitor patients risks based allegations plaintiffs asserted claims products liability negligence fraud breach warranty violations state consumer protection laws plaintiffs seek compensatory statutory punitive damages restitution four federal lawsuits pending us district court central district california dechow action us district court middle district louisiana hills action us district court western district louisiana pierot action us district court northern district california dowdy action based allegations similar raised holley action addition five pending federal actions three lawsuits based plaintiffs allegations similar raised holley action pending california state court lujano martinez grim actions filed motions dismiss holley dowdy hills pierot lujano actions motion dismiss lujano action granted plaintiffs ' strict products liability claim denied remaining claims motions dismiss remain pending also plan file motions dismiss dechow martinez grim actions intend vigorously defend actions believe cases without merit predict ultimate outcome plaintiffs successful claims could required pay significant monetary damages matters party various legal actions arose ordinary course business believe legal actions material adverse impact consolidated business financial position results operations commitments normal course business enter various firm purchase commitments primarily related active pharmaceutical ingredients certain inventory related items december commitments next five years approximately million million million million million amounts related active pharmaceutical ingredients represent minimum purchase commitments actual payments purchases related active pharmaceutical ingredients certain inventory related items billion billion billion stockholders equity stock repurchase programs first quarter board directors authorized billion stock repurchase program program repurchases may made open market privately negotiated transactions program commenced april billion stock repurchase program authorized board directors january program completed december remaining authorized repurchase amount program billion following table summarizes stock repurchases abovedescribed programs millions except per share data year ended december shares repurchased retired amount average price per share notes repurchases program includes million shares repurchased billion program million shares repurchased billion program addition repurchases stock repurchase programs repurchased shares common stock withheld us employee restricted stock awards satisfy applicable tax withholding obligations immaterial excluded table use par value method accounting stock repurchases par value method common stock first charged par value shares involved excess cost shares acquired par value allocated apic based estimated average sales price per issued share excess amounts charged retained earnings following table summarizes reduction common stock apic charge retained earnings result stock repurchases millions year ended december reduction common stock apic charge retained earnings dividends following table summarizes cash dividends declared common stock millions except per share data dividend per share amount dividend per share amount first quarter second quarter third quarter fourth quarter total restricted stock performancebased stock units dividend equivalent rights entitling holders dividend equivalents paid upon vesting share underlying units february announced board directors declared quarterly cash dividend per share common stock payment date march stockholders record close business march future dividends subject declaration board directors preferred stock million shares authorized preferred stock issuable series board authorized determine designation powers preferences rights series preferred stock outstanding december accumulated comprehensive income loss following table summarizes changes aoci component net tax millions unrealized gains losses unrealized gains foreign currency availableforsale losses translation securities cash flow hedges total balance december comprehensive income loss reclassifications amounts reclassified accumulated comprehensive income net current period comprehensive income loss balance december reclassifications retained earnings result adoption new accounting standards balance january net unrealized gain loss reclassifications net income net current period comprehensive income loss balance december amounts reclassified net income gains losses cash flow hedges recorded part product sales consolidated statements income see note derivative financial instruments additional information amounts reclassified net income gains losses availableforsale debt securities recorded part income expense net consolidated statements income employee benefits provide share based compensation form various types equitybased awards including restricted stock units rsus performancebased restricted stock units psus stock options compensation expense recognized consolidated statements income based estimated fair value award grant date estimated fair value rsus based closing price common stock psus estimated fair value based either monte carlo valuation methodology stock price date grant stock option awards estimated fair value based blackscholes option valuation model equity incentive plan may stockholders approved adopted gilead sciences inc equity incentive plan amended plan plan broad based incentive plan provides grant equitybased awards including stock options restricted stock units restricted stock awards performance awards employees directors consultants plan authorized issuance total million shares common stock december total million shares remain available future grant plan stock options plan provides option grants designated either nonqualified incentive stock options prior january granted nonqualified incentive stock options stock options granted january nonqualified stock options plan employee stock options granted prior generally vest five years stock options granted starting generally vest three four years options exercisable period exceed contractual term ten years date stock options issued granted prices less fair market value common stock grant date stock option exercises settled common stock plans previously authorized available pool shares following table summarizes activity related information stock option plans option grants presented table exercise prices less fair value underlying common stock grant date weighted weightedaverage aggregate average remaining intrinsic shares exercise price contractual term value thousands dollars years millions outstanding december granted forfeited expired exercised outstanding december exercisable december expected vest net estimated forfeitures december aggregate intrinsic value represents value closing stock price last trading day year excess weightedaverage exercise price multiplied number options outstanding exercisable total intrinsic value options exercised million million million weightedaverage grant date fair value stock options granted per share per share per share weightedaverage grant date fair value stock options granted higher due replacement awards granted connection acquisitions kite cell design labs december million unrecognized compensation cost related stock options expected recognized estimated weightedaverage period years performancebased restricted stock units plan grant psus vest upon achievement specified market performance goals could include achieving total shareholder return compared predetermined peer group achieving revenue targets actual number common shares ultimately issued calculated multiplying number psus payout percentage ranging awards generally vest committee subcommittee board determined specified market performance goals achieved fair value psu estimated date grant performance objectives defined grants depending terms award fair value date grant determined based either monte carlo valuation methodology closing stock price date grant addition also granted psus certain employees plan vesting awards subject achievement specified individual performance goals typically within one year period fair value award equal closing price common stock grant date following table summarizes activity related information psus weighted average grant date fair value per shares share thousands dollars outstanding december granted vested forfeited outstanding december note weightedaverage grantdate fair value per share excludes shares related grants currently grant date performance objectives yet defined weightedaverage grant date fair value psus granted per share per share per share total grant date fair value vested psus million million million total fair value respective vesting dates million million million recognized stockbased compensation expenses million million million related psus december million unrecognized compensation costs related psus expected recognized estimated weightedaverage period years restricted stock units grant timebased rsus certain employees part annual employee equity compensation review program well new hire employees nonemployee members board rsus share awards entitle holder receive freely tradable shares common stock upon vesting rsus generally vest three four years date grant fair value rsu equal closing price common stock grant date following table summarizes rsu activities related information weighted average grant date fair value per shares share thousands dollars outstanding december granted vested forfeited outstanding december weightedaverage grant date fair value rsus granted per share per share per share total grant date fair value vested rsus million million million total fair value respective vesting dates million million million december million unrecognized compensation cost related unvested rsus expected recognized weightedaverage period years employee stock purchase plan employee stock purchase plan international employee stock purchase plan together amended espp employees purchase shares common stock based percentage compensation subject certain limits purchase price per share equal lower fair market value common stock offering date purchase date prior espp offered twoyear lookback feature well automatic reset feature provides offering period reset new lowerpriced offering offering price new offering period less current offering period beginning first quarter lookback feature espp offering periods became sixmonths espp purchases settled common stock espps previously authorized available pool shares million shares issued espp million total million shares common stock authorized issuance espp million shares available issuance espp december stockbased compensation following table summarizes total stockbased compensation expenses included consolidated statements income millions year ended december cost goods sold research development expenses selling general administrative expenses stockbased compensation expense included total costs expenses income tax effect stockbased compensation expense net tax stockbased compensation recognized expense requisite service periods consolidated statements income using straightline expense attribution approach reduced estimated forfeitures estimate forfeitures based historical experience valuation assumptions fair value options granted plan purchases espp estimated grant purchase dates using blackscholes option valuation model blackscholes option valuation model developed use estimating fair value traded options vesting restrictions fully transferable addition option valuation models require input highly subjective assumptions including expected stock price volatility expected award life used following assumptions calculate estimated fair value awards year ended december expected volatility stock options espp expected term years stock options espp riskfree interest rate stock options espp expected dividend yield fair value stock options granted calculated using single option approach use blend historical volatility along implied volatility traded options common stock determine expected volatility expected term stockbased awards represents weightedaverage period awards expected remain outstanding estimate weightedaverage expected term based historical cancellation historical exercise data related stock options well contractual term vesting terms awards riskfree interest rate based upon observed interest rates appropriate term stockbased awards dividend yield based history expectation dividend payouts deferred compensation maintain retirement saving plan eligible us employees may defer compensation income tax purposes section k internal revenue code gilead sciences k plan certain foreign subsidiaries maintain defined benefit plans required local regulatory requirements total matching contribution expense gilead sciences k plan defined benefit plans million million million maintain deferred compensation plan directors key employees may defer compensation amounts deferred participants deposited rabbi trust total assets liabilities associated deferred compensation plan million december million december net income per share attributable gilead common stockholders basic net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock outstanding period diluted net income per share attributable gilead common stockholders calculated based weightedaverage number shares common stock outstanding dilutive securities outstanding period potentially dilutive shares common stock resulting assumed exercise outstanding stock options equivalents assumed conversion outstanding convertible notes assumed exercise warrants related outstanding convertible notes determined treasury stock method convertible notes associated warrants settled excluded stock options equivalents approximately million million million weightedaverage shares common stock outstanding respectively computation diluted net income per share attributable gilead common stockholders effect antidilutive following table shows calculation basic diluted net income per share attributable gilead common stockholders millions except per share amounts year ended december net income attributable gilead shares used per share calculation basic effect dilutive securities stock options equivalents conversion spread related convertible notes warrants related convertible notes shares used per share calculation diluted net income per share attributable gilead common stockholders basic net income per share attributable gilead common stockholders diluted segment information one operating segment primarily focuses discovery development commercialization innovative medicines areas unmet medical need therefore results operations reported consolidated basis consistent internal management reporting reviewed chief operating decision maker chief executive officer interim chief executive officer see note revenues summary disaggregated revenues product geographic region revenues major customers following table summarizes revenues customers individually accounted total revenues percentage total revenues year ended december amerisourcebergen corp cardinal health inc mckesson corp longlived assets net book value property plant equipment less office computer equipment united states billion december billion december billion december corresponding amount international locations million december million december million december individual international locations accounted less ten percent total balances income taxes income provision income taxes consists following millions year ended december domestic foreign total income provision income taxes provision income taxes consists following millions year ended december federal current deferred state current deferred foreign current deferred provision income taxes provision income taxes included million deferred tax charge previously acquired intangible assets resulting transfer assets wholly owned subsidiaries provision income taxes included billion provisional charge income tax expense related tax reform enacted december december tax reform signed law making significant changes internal revenue code amended changes include limited corporate tax rate decrease effective tax years beginning december repatriation tax deemed repatriated earnings foreign subsidiaries implementation modified territorial tax system effect subjecting earnings foreign subsidiaries us taxation global intangible lowtaxed income gilti result recorded provisional charge income tax expense billion december included provisional million deferred tax benefit related remeasurement certain deferred tax assets liabilities billion provisional charge related transition tax mandatory deemed repatriation accumulated foreign earnings accounting income tax effects tax reform completed accordance sab result recorded million net tax charge income tax provision primarily relating deferred tax revaluation partially offset refinement provisional estimate transition tax december accrued federal liability transition tax billion payable eight year period december accrued federal liability transition tax billion included longterm income taxes payable consolidated balance sheets decrease billion primarily due billion payments million refinements provisional estimate year ended december repatriated billion cash cash equivalents marketable securities parent company headquartered united states prior enactment tax reform earnings considered indefinitely reinvested us taxes provided us taxes provided earnings accrual transition tax additionally completed evaluation accounting policy election required regard tax gilti fasb allows companies adopt policy election account tax gilti one two methods account tax gilti component tax expense period tax incurred period cost method ii account tax gilti companys measurement deferred taxes deferred method elected account tax gilti period cost method reconciliation federal statutory tax rate applied income taxes effective tax rate summarized follows year ended december federal statutory rate state taxes net federal benefit foreign earnings different rates research credits us tax foreign earnings deferred tax charge acquired intangibles transition tax deferred tax revaluation settlement tax examinations effective tax rate deferred income taxes reflect net tax effects temporary differences carrying amounts assets liabilities financial reporting purposes amounts used income tax purposes significant components deferred tax assets liabilities follows millions december deferred tax assets net operating loss carryforwards stockbased compensation reserves accruals currently deductible deferred revenue depreciation related research credit carryforwards net total deferred tax assets valuation allowance valuation allowance total deferred tax assets deferred tax liabilities intangibles total deferred tax liabilities net deferred tax assets liabilities valuation allowance million million december respectively increase valuation allowance primarily related certain kite tax attributes certain foreign jurisdictions sufficient history profit realize benefit losses morelikelythannot basis december us federal net operating loss carryforwards approximately million federal net operating loss carryforwards start expire utilized also federal tax credit carryforwards approximately million start expire utilized addition state net operating loss tax credit carryforwards approximately billion million respectively state net operating loss tax credit carryforwards start expire utilized utilization net operating losses tax credits may subject annual limitation due ownership change limitations provided internal revenue code amended similar state provisions annual limitation may result expiration net operating losses credits utilization file federal state foreign income tax returns united states many foreign jurisdictions federal income tax purposes statute limitations open onwards onwards california income tax purposes certain acquired entities statute limitations open years inception due utilization net operating losses credits carried prior years income tax returns subject audit federal state foreign tax authorities currently examination irs tax years various state foreign jurisdictions differing interpretations tax laws regulations result significant disputes may arise tax authorities involving issues timing amount deductions allocations income among various tax jurisdictions periodically evaluate exposures associated tax filing positions total unrecognized tax benefits billion billion december recognized would reduce effective tax rate period recognition include interest penalties related unrecognized tax benefits part provision income taxes consolidated statements income accrued interest penalties related unrecognized tax benefits million million december respectively december believe reasonably possible unrecognized tax benefits decrease approximately million next months due potential settlements taxing authorities following rollforward total gross unrecognized tax benefits millions december balance beginning period tax positions related current year additions reductions tax positions related prior years additions reductions settlements lapse statute limitations balance end period selected quarterly financial information unaudited following amounts millions except per share amounts st quarter nd quarter rd quarter th quarter total revenues gross profit product sales net income net income attributable gilead net income per share attributable gilead common stockholders basic net income per share attributable gilead common stockholders diluted total revenues gross profit product sales net income loss net income loss attributable gilead net income loss per share attributable gilead common stockholders basic net income loss per share attributable gilead common stockholders diluted notes amounts fourth quarter included million million impairment noncash tax charge related intangible assets acquired kite pharma inc respectively inventory reserves million excess raw materials primarily due sustained decrease demand harvoni see note inventories note intangible assets note income taxes notes consolidated financial statements included item annual report additional details amounts fourth quarter included unfavorable impact per basic share per diluted share factors noted december recorded billion net charge per basic share per diluted share related enactment tax cuts jobs act see note income taxes notes consolidated financial statements included item annual report additional details gilead sciences inc schedule ii valuation qualifying accounts millions balance beginning additionscharged balance end period expense deductions period year ended december accounts receivable allowances sales return allowance valuation allowances deferred tax assets year ended december accounts receivable allowances sales return allowance valuation allowances deferred tax assets year ended december accounts receivable allowances sales return allowance valuation allowances deferred tax assets notes allowances doubtful accounts cash discounts chargebacks item changes disagreements accountants accounting financial disclosure applicable item controls procedures evaluation disclosure controls procedures evaluation december carried supervision participation management including interim chief executive officer chief financial officer effectiveness disclosure controls procedures defined rule ae securities exchange act amended exchange act controls procedures company designed ensure information required disclosed company reports files submits exchange act recorded processed summarized reported within time periods specified securities exchange commissions rules forms information accumulated communicated companys management including interim chief executive officer chief financial officer appropriate allow timely decisions regarding required disclosure based upon evaluation interim chief executive officer chief financial officer concluded disclosure controls procedures effective december b managements report internal control financial reporting management responsible establishing maintaining adequate internal control financial reporting term defined rule af exchange act internal control system designed provide reasonable assurance regarding preparation fair presentation financial statements external purposes accordance generally accepted accounting principles internal control systems matter well designed inherent limitations provide reasonable assurance objectives internal control system met supervision participation management including interim chief executive officer chief financial officer conducted evaluation effectiveness internal control financial reporting based criteria established committee sponsoring organizations treadway commission coso internal controlintegrated framework based evaluation concluded internal control financial reporting effective december independent registered public accounting firm ernst young llp audited consolidated financial statements included item annual report issued report internal control financial reporting december report audit internal control financial reporting appears c changes internal control financial reporting management including interim chief executive officer chief financial officer evaluated changes internal control financial reporting occurred quarter ended december concluded change quarter materially affected reasonably likely materially affect internal control financial reporting report independent registered public accounting firm shareholders board directors gilead sciences inc opinion internal control financial reporting audited gilead sciences incs internal control financial reporting december based criteria established internal controlintegrated framework issued committee sponsoring organizations treadway commission framework coso criteria opinion gilead sciences inc company maintained material respects effective internal control financial reporting december based coso criteria also audited accordance standards public company accounting oversight board united states pcaob consolidated balance sheets company december related consolidated statements income comprehensive income stockholders equity cash flows three years period ended december related notes financial statement schedule listed index item report dated february expressed unqualified opinion thereon basis opinion companys management responsible maintaining effective internal control financial reporting assessment effectiveness internal control financial reporting included accompanying managements report internal control financial reporting responsibility express opinion companys internal control financial reporting based audit public accounting firm registered pcaob required independent respect company accordance us federal securities laws applicable rules regulations securities exchange commission pcaob conducted audit accordance standards pcaob standards require plan perform audit obtain reasonable assurance whether effective internal control financial reporting maintained material respects audit included obtaining understanding internal control financial reporting assessing risk material weakness exists testing evaluating design operating effectiveness internal control based assessed risk performing procedures considered necessary circumstances believe audit provides reasonable basis opinion definition limitations internal control financial reporting companys internal control financial reporting process designed provide reasonable assurance regarding reliability financial reporting preparation financial statements external purposes accordance generally accepted accounting principles companys internal control financial reporting includes policies procedures pertain maintenance records reasonable detail accurately fairly reflect transactions dispositions assets company provide reasonable assurance transactions recorded necessary permit preparation financial statements accordance generally accepted accounting principles receipts expenditures company made accordance authorizations management directors company provide reasonable assurance regarding prevention timely detection unauthorized acquisition use disposition companys assets could material effect financial statements inherent limitations internal control financial reporting may prevent detect misstatements also projections evaluation effectiveness future periods subject risk controls may become inadequate changes conditions degree compliance policies procedures may deteriorate ernst young llp san jose california february item b information applicable part iii item directors executive officers corporate governance information required item concerning directors executive officers incorporated reference sections definitive proxy statement filed securities exchange commission pursuant regulation connection annual meeting stockholders proxy statement headings gilead board directors nominees board structure executive officers section beneficial ownership reporting compliance written code ethics applies directors employees including executive officers including without limitation principal executive officer principal financial officer principal accounting officer controller persons performing similar functions code ethics available website httpwwwgileadcom investors section corporate governance intend disclose future amendments certain provisions code ethics waivers code ethics granted executive officers directors website within four business days following date amendment waiver item executive compensation information required item incorporated reference sections proxy statement headings executive compensation committees board directors compensation committee report compensation nonemployee board members item security ownership certain beneficial owners management related stockholder matters information required item incorporated reference item annual report heading equity compensation plan information section proxy statement heading security ownership certain beneficial owners management item certain relationships related transactions director independence information required item incorporated reference sections proxy statement headings gilead board directors board processes item principal accountant fees services information required item incorporated reference section proxy statement heading principal accountant fees services part iv item